SECURITIES AND EXCHANGE COMMISSION
FORM 10-K
(Mark One)
þ
|
ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
For the fiscal year ended January 1, 2005 |
OR
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [NO FEE REQUIRED] |
|
For the transition period from to |
Commission File Number 0-15386
CERNER CORPORATION
Delaware
(State or other jurisdiction
of incorporation or organization)
43-1196944
(I.R.S. Employer
Identification Number)
2800 Rockcreek Parkway
North Kansas City, Missouri 64117
(816) 221-1024
(Address of principal executive offices, including zip code;
Registrants telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: NONE
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.01 per share
Preferred Stock Purchase Rights
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o
Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act rule 12b-2).
Yes þ No o
The aggregate value of the registrants voting and non-voting common equity held by non-affiliates of the registrant as of June 25, 2004 was $1,285,888,117.
At February 28, 2005, there were 36,781,069 shares of Common Stock outstanding, of which 7,217,797 shares were owned by affiliates. The aggregate market value of the outstanding Common Stock of the Registrant held by non-affiliates, based on the closing sale price of such stock on February 28, 2005, was $1,540,246,471.
Documents incorporated by reference: portions of the Registrants Proxy Statement for the 2005 Annual Meeting of Shareholders to be held on May 27, 2005 are incorporated by reference in Part III hereof.
Item 1. Business
Overview
Cerner Corporation (Cerner or the Company) is a Delaware business incorporated in 1980. The Companys corporate headquarters are located at 2800 Rockcreek Parkway, North Kansas City, Missouri 64117. Its telephone number is (816) 221-1024. The Companys Web site address is www.cerner.com. The Company makes available free of charge, on or through its Web site, its annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission.
Cerner is taking the paper chart out of healthcare, eliminating error, variance and unnecessary waste in the care process. With more than 1,500 clients worldwide, Cerner is a leading supplier of healthcare information technology. Cerner® solutions give end users secure access to clinical, administrative and financial data in real time. Consumers retrieve appropriate care information and educational resources via the Internet.
Cerner implements these solutions as stand-alone, combined or enterprise-wide systems. Cerner solutions can be managed by the Companys clients or via an application outsourcing/hosting model. Cerner provides hosted solutions from its data center in Lees Summit, Missouri.
Cerner solutions are designed and developed using the Cerner Millennium ® architecture. The Cerner Millennium architecture is a state-of-the-art technology infrastructure that combines clinical, financial and management information solutions. It provides access to an individuals electronic medical record at the point of care and organizes information for the specific needs of the physician, nurse, laboratory technician, pharmacist or other care provider, as well as for front and back office professionals.
Healthcare organizations utilize data gathered and stored within the Cerner Millennium architecture to improve the safety, efficiency and productivity of the entire enterprise. The Cerner Millennium architecture is designed to deliver medical knowledge and content to the point of care to help clinicians predict outcomes of treatment plans and deliver the most effective care.
The Healthcare Industry
During 2004, stories of medical errors grabbed the nations attention, and the cost of healthcare services continued to rise. As a result, several trends accelerated, including measures to increase quality through pay-for-performance initiatives and a movement toward consumer- and employer-driven care.
Healthcare Lags Other Industries in Technology Adoption
The healthcare industry continues to lag other markets in its adoption of technology to streamline processes, increase safety and create cost efficiencies. For example, the finance industry spends 8.6 percent of operating budget on technology while healthcare spends only 3 percent, according to the Information Week 500 study conducted in 2004. The need for increased use of technology in the delivery of healthcare appears to be reaching critical mass.
In the first half of 2004, healthcare costs rose 7.5 percent, according to the Center for Studying Health System Change (HSC) and the Employee Benefit Research Institute (EBRI). This number is high when compared to the 5.9 percent increase in per capita gross domestic product. Additionally, the cost of hospital operations increased 8 percent in 2004, representing the largest one-year jump in more than 10 years.
As consumers and healthcare organizations struggle to contain costs, many entities are driving incentives for healthcare organizations to increase care quality. Pay-for-performance efforts, for example, seek to align quality improvement with financial incentives rather than volume. To date, more than 100 plans exist, and many of them are moving toward structured measures, which include the use of healthcare information technology (HIT) and better outcomes, including both clinical and patient satisfaction. For
2
example, the Centers for Medicare and Medicaid Services (CMS) is testing financial incentives to reward hospitals that demonstrate high quality performance with its Premier Hospital Quality Incentive, which rewards organizations in acute care. For ambulatory settings, CMS Doctors Office Quality (DOQ) project develops and tests a comprehensive, integrated approach to measuring the quality of care for chronic disease and preventive services. These efforts are intended to address rapidly increasing healthcare costs and quality of care issues by promoting a best practices approach and stimulating quality improvement and cost savings.
Consumer- and Employer-Driven Healthcare Become More Prevalent
While healthcare spending in the U.S. has held steady over the past two years, insurance costs continue to increase at a double-digit pace, forcing many employers to either shift the costs to employees or drop coverage altogether. According to the California-based Kaiser Family Foundation, in 2003, the number of employees covered by employer-sponsored health insurance dropped to 45 percent, down from 53 percent in 1999. Additionally, there are now 45 million uninsured Americans, an increase of 3.2 percent since 2002. From 2000 to 2004, the average family health insurance premium increased 59 percent.
Unfortunately, experts predict that insurance costs will continue to rise. In a USA Today article, UBS Analyst William McKeever predicted an insurance premium increase between 9 percent and 10 percent for 2005. As a result, employers and consumers are looking to minimize expenses, and an estimated 50 percent of employers have moved to consumer-driven health plans. These plans give consumers greater control and financial responsibility as they select the most cost effective services and prescriptions. Forrester Research predicts that the consumer-driven health plan membership will triple by 2005, making it the fastest-growing health plan sector.
In addition to consumers, many employers are also taking action to control costs and increase quality. Through employer-driven health plans, companies encourage employees to utilize hospitals that meet specific quality criteria. As an example, The Boeing Company established a plan in 2002 to encourage its employees to access hospitals that meet criteria developed by The Leapfrog Group, a coalition of 160 companies working to improve the safety, quality and affordability of healthcare. Hospitals are evaluated on their ability to meet these quality standards, such as the use of computerized physician order entry (CPOE), and certain union groups are encouraged to use the identified organizations over other hospitals. If the participating hospital meets national patient safety standards for specific procedures, the hospital stay is eligible for a benefit incentive payment of 100 percent. Those who select another facility pay 5 percent of their hospital bill, which can often equate to hundreds or thousands of dollars.
These quality initiatives place pressure on hospitals to invest in information technology to remain competitive, and Cerners technology is taking part in leading the way with respect to HIT solutions.
Patient Safety Remains in Forefront of National Agenda
The year 2004 marked the fifth anniversary of a report by the Institute of Medicine (IOM) that cited an unacceptably high rate of medical errors that resulted in an estimated 44,000 to 98,000 deaths per year in the United States. This report became a catalyst for improvement in healthcare as experts cited the numerous flaws associated with a paper-based system. While the report exposed the high rate of error, the progress made since its publication is unknown. This is due in large part to fragmented efforts to report medical errors.
Only with a cohesive, comprehensive strategy can patient safety goals be achieved. Cerners proven CPOE solution, with 65 acute care and 313 ambulatory live sites, can provide organizations with the clinical functionality and executable knowledge to minimize errors and improve compliance with standards at the point of care.
2004 may well be recognized as the year that the electronic medical record (EMR) entered the national political agenda. Starting in January with the State of the Union address, President Bush called for increased use of computerized health records to reduce costs, improve care and lower the risk of error. He also established a goal of having an EMR for most Americans within 10 years.
3
Momentum continued to build in April when the Health Level Seven (HL7) organization announced the passing of its ballot that created a model and accompanying standards for electronic health records. This initiative will aid the adoption of the technology by creating a common platform for their use.
In May, President Bush confirmed his commitment to HIT with the appointment of Dr. David Brailer as the first national health infrastructure technology coordinator. In his position, Dr. Brailer is tasked with bringing together the fragmented segments of healthcare to improve quality and reduce costs.
In July, Neal Patterson, Cerner chairman and CEO, participated in the second annual National Health Information Infrastructure (NHII) Summit in Washington, D.C., during which industry leaders discussed plans to transform the delivery of healthcare by building new health information infrastructure, including electronic health records and a nationwide network to link health records. While there, Patterson suggested a similar urgency as President Bushs 10-year call for EMRs stating, We are the generation that has to do this work.
As the year came to a close, Dr. Brailer and Dr. Mark McClellan, administrator of CMS, spoke at Cerners Health Care Leadership Forum and Cerner Health Conference, both held in October. They both talked about the growing momentum around HIT and the important role the marketplace can play in hastening its adoption. 2005 promises to bring additional and important developments. Cerner plans to play a role in shaping them.
The Cerner Vision
Cerners vision has evolved from a fundamental thought: Healthcare should not be organized around an encounter; it should revolve around the individual. This concept led to Cerners Community Health Model and the creation of the person-centric Cerner Millennium architecture a truly unified, enterprise-wide architecture. The Community Health Model encompasses four steps:
| Automate the Core Processes | |||
| Connect the Person | |||
| Structure the Knowledge | |||
| Close the Loop |
Automate the Core Processes
As long as medical information is isolated in a paper record, the inadequacies of todays healthcare delivery system will likely remain. Nurses and pharmacists will be forced to interpret potentially illegible and incomplete orders. Physicians will not benefit from the real-time, contextual reference information available in automated solutions. And clinicians throughout a healthcare organization will continue to search for the single copy of the paper-based record; when it is not readily available, they may be forced to make critical care decisions without adequate information.
The elimination of the paper record can improve quality and safety, increase productivity, and generate better documentation from which clinical outcomes, financial performance and resource utilization can be benchmarked and analyzed.
With an EMR, clinicians view demographic information, medical history, lab results, vital signs and treatment plans, along with notes from healthcare team members. Guidelines and pathways relevant to the persons medical condition help the physician make the best possible decisions in diagnosing and treating the patient. This comprehensive view of the persons health helps ensure safer and higher-quality care.
Once all the steps of healthcare are captured electronically, the enhanced documentation will create the foundation for data collection that can become the backbone for structuring the knowledge of healthcare.
In addition to automating workflow, technology is essential in order to eliminate error, variance, waste, delay and friction all of which contribute to declines in healthcare quality and increases in medical error. HIT can eliminate these factors, leading to an overall cost reduction in healthcare.
4
Connect the Person
Cerner is dedicated to helping build a new medium between the person and the physician, which empowers the individual and delivers higher-quality healthcare. A cultural shift toward self-directed care is breeding a new consumerism in healthcare. With a personal health record, individuals can store and access their medical information securely from anywhere they have Internet access. When combined with personalized health content, consumers gain a better sense of the care they are receiving and the options available to them. They communicate better with providers and more proactively manage their healthcare.
Structure the Knowledge
Cerner is dedicated to building information systems that treat every clinical decision as a learning event. Cerner solutions enable the industry to structure, store and study the application and outcomes of medical practice.
Cerner believes medicine must have a structure that allows physicians to record treatment and outcomes in such a way that it can be compared and contrasted with other methods. A common nomenclature that can exactly capture the meaning of input from physicians and clinicians is a necessary first step.
Cerner solutions store healthcare data and provide a framework for comparability. This structured data enables physicians to make sense of and glean value from the information that is gathered through automated processes and connected persons. Cerner believes that without a knowledge framework, data collected will provide no real benefit. By building this structure, Cerner opens the door for every encounter with a patient and every piece of new knowledge to be catalogued, measured and analyzed. This knowledge framework will allow providers to deliver better care and develop an improved understanding of medicine.
Close the Loop
Cerner is dedicated to building information systems that deliver evidence-based medicine, dramatically reducing the average time from the discovery of an improved method to the change in medical practice.
Advances in technology offer great opportunities in healthcare and must be used to deliver better care faster. The information learned must be applied. Today, patients may wait as long as 10 years before new medical knowledge reaches widespread use. With systems designed to embed evidence-based medicine inside the clinicians workflow ¾ using pathways, guidelines and alerts ¾ physicians know that the best science can be leveraged in every medical decision. This leads to reduced variance and better outcomes.
Evolution of Community Health Model Connects Larger Communities
Over the next 25 years, medicine will become increasingly personalized and technology will become more accessible. Cerner has created four business areas to address this evolutionary progress. These segments, referred to by the Company as grid services, represent the utility-like potential of the services Cerner will offer to large communities of users. The underlying principles of this initiative are to:
| Connect all stakeholders in the healthcare system; | |||
| Create a secure, transparent and open network for data sharing; and | |||
| Remove the clinical, financial and administrative friction. |
The first grid is the physician and metro grid, which focuses on leveraging Cerners physician practice organization and on delivering a broad range of financial and clinical solutions to physician offices. The other grids are the state and regional grid, which drives the Companys State and Regional Health Information Organization (RHIO) strategy and its next version of e-prescribing; the condition and disease management grid, which securely connects individuals with chronic conditions, such as diabetes and asthma, with their healthcare providers; and the transactional services grid, which seeks to eliminate friction in the healthcare system by supporting the processing and management of healthcare transactions.
5
The Cerner Strategy
Key elements of the Companys business strategy include:
Penetrate the integrated healthcare provider market. Large healthcare systems represent a significant component of the healthcare information technology market. These organizations focus on improving safety and reducing costs through operating efficiencies. Cerners enterprise-wide, person-centric clinical and management solutions provide the technology to manage healthcare across an organization, significantly reducing costs, improving the efficiency of delivery and enhancing the quality of care.
Increase market share in individual domains and further penetrate the existing client base by cross-selling additional Cerner solutions. Cerner expects continued growth in clinical domain systems for specific markets such as nursing, physician office, laboratory, pharmacy, radiology, surgery, emergency medicine and cardiology, as institutions look to restructure and reengineer these high-cost centers.
Focus on independent physician practices. As healthcare becomes increasingly personalized, access to personal patient information is critical for both large integrated networks and independent physician practices. As such, Cerner will concentrate significant efforts to reaching physician practices of all sizes to systematize the healthcare process.
As part of these efforts, in January 2005, Cerner acquired the medical division of VitalWorks, Inc., a leader in the private physician office information technology market. This transaction expands Cerners presence in the physician practice market, an area which is expected to increase considerably as the federal government continues its push to bring medical information to the point of care. This acquisition, which adds 3,500 physician practices, builds on Cerners already substantial hospital-affiliated physician client base, giving it additional reach across the entire spectrum of the $4 billion ambulatory market.
Create the perfect client experience. As a client-focused company, Cerner recognizes that relationships are as critical to success as breadth and depth of solutions. As a result, its approach to client services is broad, encompassing everything from implementation and adoption to ongoing service and support. Once these elements are in place, healthcare organizations can realize the full benefits of HIT and achieve their goals of higher quality care and patient safety.
HIT purchasing decisions are expensive and often present a great risk to both the sponsoring organization and the ultimate decision-maker. Cerner is easing this process by creating a comprehensive approach to implementation and management of these complex systems. The Company is automating processes by creating a specific methodology designed to reduce the design/build/maintenance efforts by up to 50 percent. This effort is intended to significantly reduce implementation time and to lower the Companys clients cost of ownership of Cerner solutions. The Cerner strategy also calls for easier system management, which will contribute to Cerners ability to achieve its goal of guaranteeing an industry-leading application availability rate.
Remain committed to a common architecture. Because Cerner believes that the constituents in health management need to work together to benefit defined populations in a community, the Company has made a commitment to a single, unified architecture as the platform for its health information and management systems. The Cerner Millennium architecture is scalable on a linear basis, using either Cerner compatible modules for process-oriented applications or competitive systems interfaced using open system protocols.
Develop innovative solutions and services. Building upon the Cerner Millennium architecture, Cerner intends to continue to lead the industry through new innovations. These solutions and services will complement existing solutions, address clients emerging HIT needs and employ technological advances.
In 2004, Cerner introduced PathNet Helix , a breakthrough genomics solution for the laboratory. This first-of-its-kind solution allows genetic information to be stored in an electronic medical record, providing
6
immediate access to information from genetic tests and helping clinicians plan the most effective therapy and treatment.
Additionally, the Company launched INet ® Virtual , a cutting-edge solution for critical care units to achieve real-time data sharing across all domains of care, thus eliminating the communication barriers between care providers. The solution went live in November at the Borgess Medical Center in Kalamazoo, Michigan, a member of Ascension Health, the largest nonprofit health care system in the United States. This implementation, which will form the foundation for the national design for Ascension Health, was the first INet Virtual conversion for Cerner.
Cerner is committed to offering solutions that improve critical care quality, processes, safety and outcomes. Its vision is for a single critical care quality improvement solution that incorporates all standards and evidence. In February 2004, Cerner acquired Project IMPACT TM , a prominent solution in critical care performance benchmarking. This solution provides a unique complement to the Cerner critical care suite of solutions by marrying Project IMPACT with the decision-support and risk-adjustment capabilities of APACHE ® .
Additionally, the PowerInsight ® data-warehouse solution for healthcare business intelligence helps to transform healthcare by providing a foundation for the accurate measurement of a healthcare organizations current business, delivering specific information and services required for continuous performance improvement.
Continue pursuit of excellence in implementations. Since the introduction of the Cerner Millennium architecture, Cerner has steadily decreased implementation timelines while increasing the number of solutions converted within those timelines. In 2004, Cerner turned on 1,079 Cerner Millennium applications, a 22 percent increase over 2003. This brings the total number of live applications to 3,767 at nearly 750 facilities.
Cerners prescribed practices implementation model, developed from more than 25 years of success in developing and implementing HIT solutions, is contributing to the record number of implementations. Comprised of a dedicated group of information technology consultants who specialize in Cerner Millennium implementations and work closely with clients, the team takes much of the implementation burden of database design and build activities away from the client. As a result, clients enjoy reduced time, cost and complexity of implementation.
Expand Managed Services. In addition to offering access to talent and economies of scale, there are some services that, in certain circumstances, the Company can perform better and more economically than its clients. Over the past several years, Cerner has added and offered a number of services, called Managed Services. This set of technical services includes remote hosting, application management and disaster recovery.
Build a reputation as a partner characterized by trust and integrity. In an era in which corporate financial scandals seem almost a constant in the headlines, Cerner pledges to promote trust and integrity in every client relationship it establishes. Cerners three original founders still in leadership positions at the Company today along with its long history of solid financial performance are testaments to the Companys commitment.
Continue to expand global presence . Cerner has an immense opportunity to revolutionize the practice and delivery of healthcare throughout the world through its leadership in clinical systems and patient safety. To that end, Cerner continues to make significant investments in the infrastructure development to support these efforts.
Cerner signed a contract with St. Jamess Hospital in 2004, an organization that has emerged as the largest acute general hospital in the Republic of Ireland. Cerner is providing an integrated RIS/PACS system with Scheduling and PowerChart ® for orders and results.
7
In 2004, Cerner and its partner Atos Origin (formerly SchlumbergerSema) delivered key milestones in bringing the Choose and Book system live in England. From a technical point of view, the project is the most advanced deployment of the Cerner Millennium architecture to date. The Company demonstrated that the solution could handle large volumes of transactions while meeting extremely high service level requirements. The system handled about 2.8 million service requests per hour, and the database managed 5,000 SQL executions per second. The testing validated the scalability and performance of the Cerner Millennium Web Experience architecture.
Other countries and regions around the world are taking Englands lead for a countrywide examination of HIT to modernize their healthcare systems. Across Europe, for example, there is an increased understanding of the need for improved access to information to facilitate the frequent movement of citizens across the European Union, according to a recent report by Frost & Sullivan. Cerner is optimistic about the global market and is expanding to new countries and responding to opportunities.
Solutions
Cerner Millennium solutions run on a single healthcare architecture uniquely capable of storing, retrieving and disseminating clinical and financial information across an entire health system. The Cerner Millennium solutions are dedicated to meeting the automation needs of every segment of the care continuum.
Cerner solutions can be acquired individually or as a fully unified health information system. Cerner also markets more than 200 solution options that complement Cerners major information systems. In addition, Cerner offers comprehensive consulting servicesincluding learning services, readiness assessments, planning and change management and process redesignand also sells third-party computers and related hardware to its software licensees.
Financial information regarding the Companys operating segments is included under the caption Operations by Segment under Item 7, Managements Discussion and Analysis of Financial Conditions and Results of Operations and also under the caption Segment Reporting as presented in Note 13 of the consolidated financial statements.
Enterprise Repositories
The unique architecture of Cerner Millennium solutions sets Cerner apart from the competition. A key part of the Cerner Millennium architecture is the data repositories ¾ the underlying foundation for Cerner solutions ¾ which allow healthcare organizations to manage and make use of the data collected along the healthcare continuum.
The Open Clinical Foundation® repository manages clinical information with an open, standard medical terminology, providing the foundation for the EMR.
The MultiMedia Foundation repository provides the clinical and document imaging foundation for the EMR.
Cerners solution categories include:
| Enterprise-Wide Systems, which automate processes throughout the health system enterprise, including: |
| Access Management. | |||
| Care Management. | |||
| Financial and Operational Management Systems, which automate business operations. |
| Clinical Systems, which automate critical processes across the healthcare continuum, and Clinical Centers, which provide efficiencies for ancillary departments such as laboratory and radiology. |
8
| Decision Support and Knowledge, which enhance clinical and business processes with information and actions. | |||
| Consumer, which supports Internet-based healthcare communities that effectively connect individuals, providers and health systems. | |||
| Packaged Solutions, which address key processes in healthcare. | |||
| Segment Solutions, which address issues unique to specific care settings. | |||
| Technologies for developing solutions or connecting other technologies and systems to the Cerner Millennium architecture. |
Enterprise-Wide Solutions
Access Management
The CapStone ® Enterprise Access Management System is the industrys most comprehensive suite of solutions designed to automate, integrate and streamline patient access information between and among all key points in the delivery system. Key components of this solution create the enterprise master person index (EMPI) and automate the identification, eligibility, registration and scheduling processes across hospitals, clinics, physician practices and other care delivery organizations.
Care Management
PowerChart Enterprise Clinical Data Repository is Cerners enterprise-wide electronic medical record system. It includes a robust data repository that is shared across all Cerner Millennium solutions, and a highly interactive clinicians desktop used for viewing, ordering, documenting and managing care delivery. PowerChart is unified with the PowerOrders® solution to provide Computerized Physician Order Entry (CPOE).
Financial and Operational
Cerner is leveraging its experience to bridge the gap between clinical settings and the business office, revolutionizing the revenue cycle within healthcare systems.
The ProFit® Enterprise Billing and Accounts Receivable System is Cerners patient accounting and financial management solution. The ProFit system brings together clinical and financial data to maximize reimbursement, decrease denials and gain dramatic operational efficiencies.
Cerner ProVision Document Image Management System manages document images across the entire healthcare organization, including both clinical and non-clinical departments.
The ProFile ® Health Information Management System helps meet the operations management needs of the health information management (medical records) department with functionality that simultaneously manages paper, document images and computerized records within a single application.
The Clinically Driven Workforce Management solutions align the appropriate resources based on predicted and actual demand. With this comprehensive suite of offerings, organizations are empowered to optimize existing resources while increasing patient throughput and managing employee satisfaction.
The ProCure Enterprise Supply Chain Management solutions focus on eliminating variation and clinical staff burden. By connecting materials management processes with key clinical processes, the supply chain is established as a byproduct of care delivery.
Medical Transcription Management Solutions offer unprecedented levels of accuracy and efficiency of transcribed documents by leveraging clinical data to auto-create report content.
9
Clinical Systems
Points of Care
The INet® Critical Care Management System is designed to automate the entire care process in critical care settings. It supports complete nursing documentation with automated capture of bedside monitor and device data. Physician workflow is automated with both documentation and flow sheet embedded Computerized Physician Order Entry (CPOE). Both nursing and physician workflows are enhanced with closed loop meds process and remote patient monitoring capabilities. Embedded knowledge augments patient safety with critical care specific nursing and physician documentation templates and alerts. Outcome analysis (with premier solutions like APACHE ®) is also embedded in the critical care workflow.
The CareNet® Acute Care Management System is designed to automate and streamline the work and care delivery processes for nursing and the entire acute care team. It provides the framework for accessing patient data, directing clinicians to care activities that need to be completed and managing tasks. CareNet provides improved communication and the coordination of care as it connects each member of the care team to a unified plan of care and common system. Everyone involved in the care of a patient can view an up-to-date version of the care plan, allowing physicians and nurses to make the best decisions possible. The CareNet system also promotes patient safety through access to strong clinical decision support, evidence-based nursing and knowledge-based best practices, alerts and reminders, thereby reducing errors and variability in the care process.
The CVNet® Cardiology Information System automates the processes within the cardiology department, supporting the scheduling, ordering, documentation and data capture required by professionals in the cardiology domain.
The PowerChart Oncology Information System automates the clinical decision-making and complex communication needs of the medical oncology care team. This oncology solution provides the ability to share crucial patient information across both ambulatory and acute care for management of complex, multi-encounter chemotherapy protocols, improving communication and the real-time flow of patient information across the continuum of care.
The SurgiNet ® Surgery and Anesthesia Management System is designed to automate the needs of the entire perioperative environment, including functions of professional staff and material resource scheduling, supply chain management, perioperative documentation, patient tracking, anesthesia documentation, and physiological monitoring at the bedside or in the operating room suite. The solution gives clinicians real-time access to clinical and historical patient data from past surgical events in addition to supporting planning for anesthesia care and surgical case preparation. The SurgiNet system also offers financial and operational reporting tools to analyze and support continuous improvement in total perioperative workflow.
The Cerner Womens Health Information System automates the care processes in womens centers, Ob/Gyn offices, labor and delivery units and in newborn care areas in the hospital. This solution is designed to support the clinical workflow, information needs and specific challenges faced in womens healthcare.
The FirstNet ® Emergency Department Information System provides a comprehensive solution to the challenges emergency departments face to streamline process flows, comply with Health Insurance Portability and Accountability Act and Emergency Medical Treatment and Active Labor Act regulations, comply with CMS requirements and ensure appropriate reimbursement. The FirstNet system is an emergency department clinician and management tool for quick and effective patient tracking, ordering, results and medical record review, online clinical documentation, prescription writing, patient education and evidenced-based coding.
The PowerChart Office ® Management System supports the broad range of clinical and business activities that occur within a physician office, clinic or large physician organization. This system ties the physician office together with other medical entities and automates key care team activities in both primary and specialty care settings.
10
Clinical Centers
The PathNet ® Laboratory Information System (LIS) addresses the clinical, financial and managerial needs of a comprehensive laboratory setting with unified solutions for: general laboratory, microbiology, blood bank transfusion, blood bank donor, anatomic pathology, human leukocyte antigen (HLA) and total outreach services. Innovative laboratory solutions such as patented Synoptic Reporting for Anatomic Pathology solution, the Gajema® system for outreach client service, courier, fleet and phlebotomy management, and the PathNet Helix solution for molecular diagnostic/genomics are just several examples of how PathNet continues to set the bar in the LIS market. The PathNet system automates laboratory processes while capturing crucial data for operational success and increased patient safety, ensuring the production of accurate and timely reports and the maintenance of accessible laboratory records.
The RadNet ® Radiology Information System addresses the operational and management requirements of radiology departments or services. It allows a department to replace its manual, paper-based system of record-keeping with an efficient computer-based system.
Cerner ProVision PACS (picture archival and communications system) is fully unified with Cerners radiology information system to manage storage, viewing, reporting and distribution of images. Using Cerners end-to-end, fully unified radiology information and image management systems, radiologists can improve operational efficiencies and reduce medical error.
The MultiMedia Foundation integrates images, slides, photos, audio, video and waveforms, enabling a comprehensive EMR, enterprise-wide access to images and enhanced clinical decision support.
The PharmNet ® Pharmacy Information System is a powerful solution for transforming pharmacy and medication administration processes. The PharmNet system facilitates improved patient safety and operational activities across the continuum of care. The PharmNet system puts patient safety first and foremost in support of clinical pharmacy practice. It is a complete solution offering clinical decision support, formulary management and operational support, facilitating optimal utilization of pharmacy resources.
Decision Support and Knowledge
The Discern Expert ® solution is an event-driven, rules-based decision support software application that allows users to define clinical and management rules that are applied to event data captured or generated by other applications. It supports both synchronous (real-time, interactive) processing and asynchronous (non-interactive) processing of events.
The Discern Explorer ® solution is a decision support software application unified with other Cerner Millennium clinical and management information systems that allows users to execute predetermined or ad hoc queries and reports regarding process-related data that is generated by the other applications.
Executable Knowledge ® solutions help clinicians assess and treat illnesses and improve outcomes based on the most current medical knowledge. Knowledge is customized to the individual and embedded within the Cerner Millennium architecture via order sets, plans of care, alerts and notifications including Adverse Drug Event (ADE) prevention alerts and clinical documentation. Reports measure compliance against key clinical standards to help organizations benchmark and enhance care quality.
MediSource solutions provide caregivers and consumers alike with access to drug information from Cerner Multum and the ability to perform drug interaction checking to prevent adverse events. Patient safety is enhanced through dose range checking capabilities that determine the appropriate medication dose based on the age, weight and physiology of an individual.
APACHE clinical decision support and outcomes management systems manage the clinical and financial outcomes of high-risk patients in critical and acute care.
11
The PowerInsight solution is a comprehensive healthcare intelligence and data warehouse for healthcare. It enables clinical leadership and healthcare executives to collect, measure, analyze and benchmark data, thereby deriving insights to enable positive changes in clinical processes and operational performance.
The Health Facts ® repository is Cerners comparative data warehouse for benchmarking information and services for subscribers to support their own improvement processes.
Cerner Health Insights (CHI) provides clinical insight into pharmaceutical and biotech challenges. Cerners delves deeply into the realities of clinical practice, helping its clients formulate business responses to outcomes and economic issues.
The HealthSentry bio-surveillance network collects critical biological information about potential disease outbreaks and analyzes data for specific patterns or trends.
Consumer
Cerners IQHealth ® solution is dedicated to closing the healthcare information loop by delivering the right information to the right person at the right time, and often the right person is the patient. A care delivery organization has not truly closed the loop on healthcare information until they have placed the patient at the center of care. Cerners IQHealth solution creates an online dialogue between hospital, physician and patient. Using the Internet, patients can maintain their personal health record, gain educational support and receive guidance in managing their health.
Cerners IQHealth solution empowers patients to become active members of their care team. By extending the clinical suite to include interaction with patients, healthcare providers can more efficiently deliver care and enhance the satisfaction of the community. Cerners IQHealth solution includes the consumer Web framework, personal health record, physician and consumer messaging and disease-specific modules , as well as a patient medical record view and patient appointments module.
Packaged Solutions
Computerized Physician Order Entry (CPOE)
Cerner offers a total CPOE solution ranging from basic automation to complete medication integration.
CPOE enables automated physician ordering of medications, diagnostic tests and treatment plans. Orders are checked using decision-support tools to determine if they are in line with standards and appropriate for the persons individual situation. Physicians are alerted to potential problems and prompted to consider alternatives. Actions are documented in the patients EMR.
Cerners CPOE solution facilitates safe and efficient care across multiple care venues. It goes beyond automating the ordering process by embedding the latest clinical knowledge to provide effective decision support and guidance. The solution is seamlessly unified with the EMR, pharmacy, medication administration, care documentation and ancillary systems to close the loop in the medication management process. By unifying care in this manner, Cerner CPOE helps clients address potential errors across the entire process.
Cerners CPOE solution includes a physician-centric ordering application ( PowerOrders ), a powerful decision-support engine with rules and alerts ( Discern Expert and MediSource ), and clinical documentation ( Care Documentation and more), all integrated within a robust clinical data repository ( PowerChart ).
12
PowerPOC
PowerPOC TM is a solution set of supporting, multisystem offerings that automate the documentation of medication administration and documentation of tasks related to specific physician/nursing orders at the point of care (POC). This solution set provides notification to the clinician when inconsistencies occur that could represent potential medication administration errors.
This graduated solution set facilitates patient safety through barcode verification of the Five Rights of data review and collection, as well as medical devices integration at the patient bedside. Solutions within the PowerPOC family include: CareAdmin ; CareMobile; and CareGuard solutions .
Homecare
Cerner BeyondNow provides innovative information technology solutions to the homecare industry. The HomeWorks â solution is a complete office-based homecare information management system targeting business needs in a quickly changing, fast paced environment. The HomeWorks solution manages data from the point of the first referral call to the point of the last service payment. The RoadNotes â solution enables users to extend complete patient information from point-of-care to the office system. Caregivers have access to complete patient charts, profiles and histories for the information needed to make informed decisions.
Physician Solutions
Cerner Physician Practice solutions offer high-end, leading technology software solutions to a wide variety of office-based and hospital-based medical specialties, as well as large physician networks and enterprises. This comprehensive physician practice suite enables general medicine and individual specialty practices to provide efficient, high quality care while improving reimbursements and streamlining processes.
Rather than offering a one-size-fits-all all-specialty application, Cerner Physician Practice solutions offer many specialty-specific applications and services. Specialty areas include anesthesiology, cardiology, ophthalmology, dermatology and podiatry.
Segment Solutions
Cerner also offers solutions designed for specific segments in the healthcare industry.
Cerner solutions for the Integrated Delivery Network allow organizations to serve multiple facilities, with differing needs, across various geographic locations.
Community Hospital Solutions automate clinical and business processes in the community hospital. Community Hospital Solutions suites include administrative, clinical, patient care, hospital integration and community.
Cerner solutions for the Childrens Hospital setting specifically address those issues unique to the pediatric hospital setting. Cerner solutions include content and functionality specific to meeting the unique needs of childrens hospitals, including dose range checking, weight-based dose calculation, growth charts and immunization schedules.
Cerner solutions for Academic Medical Centers allow medical centers to focus on delivering high-quality care and carry out high-level teaching and research functions . Cerners unified architecture also enhances research efforts by allowing access to information via a centralized database.
13
The Cerner Academic Education Solution is the only clinical information system adapted to support automated curricula and classroom instruction in nursing, medical and allied health schools, preparing future healthcare professionals for success in an IT-driven environment.
Technologies
The MillenniumObjects ® toolkit is a collection of reusable programming elements from the revolutionary Cerner Millennium architecture. These segments of code, or objects, allow third-party developers to create front-end applications that draw upon the data model and proven functionality of the Cerner Millennium architecture.
The Open Engine Application Gateway System facilitates the exchange of data and assists in the management of interfaces between foreign systems in a network environment. It serves as a solution kit to help write interface code.
The Open Port Interface System represents Cerners standardized technology for providing reliable foreign system, medical device and other standard interfaces in a timely manner. Message translation and data mapping are done with point-and-click solutions and a scripting environment. Communications protocols are configured via table-driven parameters. These sophisticated methodologies result in decreased implementation times and greater client satisfaction.
Software Development
Cerner commits significant resources to developing new health information system solutions. As of January 1, 2005, approximately 1,752 associates were engaged full-time in software solutions development activities. Total expenditures for the development and enhancement of the Companys software solutions were approximately $188,264,000, $179,999,000 and $149,985,000 during the 2004, 2003 and 2002 fiscal years, respectively. These figures include both capitalized and non-capitalized portions and exclude amounts amortized for financial reporting purposes.
The Company expects to continue investment and development efforts for its current and future solution offerings. As new clinical and management information needs emerge, Cerner intends to enhance its current software solutions lines with new versions released to clients on a periodic basis. In addition, Cerner plans to: expand its current software solution lines by developing additional information systems for clinical, financial, operational and/or consumer use; continue to support simultaneous use of Cerners solutions across multiple facilities; and, continue to expand in the global marketplace.
The Company is committed to maintaining open attributes in its system architecture to achieve operability in a diverse set of technical and application environments. The Company strives to design its systems to co-exist with disparate applications developed and supported by other suppliers. This effort is exemplified by Cerners Open Engine Application Gateway , Open Port Interface and MillenniumObjects solutions lines.
Sales and Marketing
The markets for Cerners HIT solutions include integrated delivery networks, physician groups and networks and their managed service organizations, managed care organizations, hospitals, medical centers, free-standing reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employer coalitions and public health organizations. To date, a substantial portion of system sales has been in clinical solutions in hospital-based provider organizations. The Cerner Millennium architecture is highly scalable, with solutions being used in hospitals ranging from fewer than 50 beds to more than 2,000 beds and managed care settings with more than 2,000,000 members. All Cerner Millennium solutions are designed to operate on HP or IBM platforms, thereby allowing Cerner to be price competitive across the full size and organizational structure range of healthcare providers. The sale of a health information system usually takes approximately nine to 18 months, from the time of initial contact to the signing of a contract.
14
The Companys executive marketing management is located in its North Kansas City, Missouri, headquarters, while its client representatives are deployed across the United States and globally. In addition to the United States, the Company, through subsidiaries and joint ventures, has sales staff and/or offices in Argentina, Australia, Belgium, Canada, Chile, France, Germany, India, Singapore, Malaysia, Spain, the United Kingdom and the United Arab Emirates. Cerners consolidated revenues include foreign sales of $64,333,000, $54,191,000 and $36,634,000 for the 2004, 2003 and 2002 fiscal years, respectively.
The Company supports its sales force with technical personnel who perform demonstrations of Cerner solutions and assist clients in determining the proper hardware and software configurations. The Companys primary direct marketing strategy is to generate sales contacts from its existing client base and through presentations at industry seminars and tradeshows. Cerner attends a number of major tradeshows each year and sponsors executive user conferences, which feature industry experts who address the HIT needs of large healthcare organizations.
Client Services
Significantly all of Cerners clients enter into software maintenance agreements with Cerner for support of their Cerner systems. In addition to immediate software support in the event of problems, these agreements allow clients the use of new releases of the Cerner solutions covered by maintenance agreements. Each client has 24-hour access to the client support staff located at Cerners world headquarters in North Kansas City, Missouri and the Companys global support organization in the United Kingdom. Most of Cerners clients also enter into hardware maintenance agreements with Cerner. These arrangements normally provide for a fixed monthly fee for specified services. In the majority of cases, Cerner subcontracts hardware maintenance to the hardware manufacturer. Cerner also offers a set of managed services that include remote hosting, application management services and disaster recovery.
Backlog
At January 1, 2005, Cerner had a contract backlog of approximately $1,191,170,000 as compared to approximately $938,221,000 at January 3, 2004. Such backlog represents system sales from signed contracts, which had not yet been recognized as revenue. The Company recognizes revenue on a percent of completion basis, based on certain milestone conditions, for its software solutions. At January 1, 2005, the Company had approximately $96,909,000 of contracts receivable, which represents revenues recognized under the percentage of completion method but not yet billable under the terms of the contract. At January 1, 2005, Cerner had a software support and maintenance backlog of approximately $347,662,000 as compared to approximately $312,887,000 at January 3, 2004. Such backlog represents contracted software support and hardware maintenance services for a period of twelve months. The Company estimates that approximately 44% percent of the aggregate backlog at January 1, 2005 of $1,538,832,000 will be recognized as revenue during 2005.
Competition
The Company faces a highly competitive environment in the HIT market. The market for HIT solutions and services is intensely competitive, rapidly evolving and subject to rapid technological change. The Companys principal existing competitors include Eclipsys Corporation, Epic Systems Corporation, GE Medical Systems, IDX Systems Corporation, iSoft Corporation, McKesson Corporation, Medical Information Technology, Inc. (Meditech), Misys Healthcare Systems and Siemens Medical Solutions Health Services Corporation, each of which offers a suite of software solutions and services that compete with many of the Companys software solutions and services. There are other competitors that offer a more limited number of competing software solutions and services. In addition, the Company expects that major software information systems companies, large information technology consulting service providers and system integrators, Internet-based start-up companies and others specializing in the healthcare industry may offer competitive software/solutions or services. The pace of change in the HIT systems market is rapid and there are frequent new software solution introductions, software solution enhancements and evolving industry standards and requirements. The Company believes that the principal competitive factors in this market include the breadth and quality of system and software solution offerings, the stability of the information systems provider, the features and capabilities of the information
15
systems, the ongoing support for the system and the potential for enhancements and future
compatible software solutions.
Other Factors Affecting The Companys Business
Information under the caption Factors That May Affect Future Results of Operations, Financial
Condition of Business included in Managements Discussion and Analysis of Financial Condition and
Results of Operations in Item 7 is incorporated herein by reference. Such information includes a
discussion of various factors that could, among other things, affect the Companys business in the
future, including: (a) variations in the Companys quarterly operating results; (b) volatility of
the Companys stock price; (c) changes in the healthcare industry; (d) significant competition; (e)
the Companys proprietary technology may be subjected to infringement claims or may be infringed
upon; (f) government regulation; (g) the possibility of product-related liabilities; (h) possible
failures or defects in the performance of the Companys software; (i) risks associated with the
Companys global operations; (j) recruitment and retention of key personnel; (k) risks related to
doing business with third party suppliers; and, (l) the potential inconsistencies in sales
forecasts compared to actual sales.
Number of Employees (Associates)
As of January 1, 2005, the Company employed 5,345 associates worldwide.
Item 2. Properties
The Companys world headquarters offices are located in a Company-owned office park in North Kansas City, Missouri, containing approximately 739,000 square feet of useable space (the Campus), inclusive of the new buildings described below. As of January 1, 2005, the Company was using approximately 736,000 square feet and substantially all of the remainder was leased to tenants. In 2004, the Company purchased approximately 12 acres of unimproved real estate adjacent to the Cerner World Headquarters for campus expansion. An access road has been built to the property; plans are underway for further development. In November 2004, the Company entered into a lease for approximately 127,000 rentable square feet of property located at 3315 North Oak Trafficway in Kansas City, Missouri. The office space, known as the Cerner Oaks Campus, will initially house associates from the Cerner Managed Services and Cerner Technologies groups. The lease contains an option to purchase the building at fair value. In the first quarter of 2002, the Company began construction of a new facility situated between the buildings located at 2800 and 2900 Rockcreek Parkway on the Campus. This facility was completed on August 1, 2003 and is approximately 123,000 gross square feet in size. This new facility, referred to as Cerners World Headquarters Building, houses offices, a cafeteria and meeting space for the Company. In 2002, the Company also began construction of a new office building located on the Campus. This facility, approximately 200,000 gross square feet in size, was completed in December 2003 and houses office and meeting space for the Company.
The Company also owns property located along the north riverbank of the Missouri River, approximately 2 miles from the Companys Campus. This property consists of an 80,000 square foot building and a 1,300-car parking garage. The building has been renovated for use as a corporate training, meeting and event center for the Company and third parties. The Company has also made use of the parking garage to meet overflow-parking demands on the Companys Campus.
As of March 2005, the Company also leased office space in: Birmingham, Alabama; Beverly Hills, California; Denver, Colorado; Alpharetta, Georgia; Overland Park, Kansas; Waltham, Massachusetts; Bel Air, Maryland; Minneapolis, Minnesota; Rochester, Minnesota; Kansas City, Missouri; Charlotte, North Carolina; Beaverton, Oregon; Houston, Texas; and Vienna, Virginia. The Company operates its primary solutions center (or data center) in leased space in Lees Summit, Missouri. Globally, the Company also leases office space in: Sydney, Australia; Brussels, Belgium; Santiago, Chile; London-Ontario, Canada; London, England; Paris, France; Aachen and Idstein, Germany; Bangalore, India; Kuala Lumpur, Malaysia; and Barcelona, Spain. In 2004, the Companys Detroit, Michigan and St. Louis, Missouri offices were closed as the Company relocated many associates to its World Headquarters Campus.
16
Item 3. Legal Proceedings
As previously disclosed, the Company received notice in April 2003 that three shareholder class action lawsuits were filed against it and five of its officers in the United States District Court for the Western District of Missouri. Subsequently, five additional shareholder class action lawsuits were filed against the Company. All of these lawsuits were filed after a decline in the Companys stock price following the Companys announcement on April 3, 2003 that the Company would not meet revenue and earnings estimates for the first quarter of 2003.
On August 20, 2003, the Court ordered that all of the lawsuits be consolidated under Case No. 03-CV-00296-DW and appointed Phil Crabtree as Lead Plaintiff. On December 1, 2003, the Lead Plaintiff filed a Consolidated Class Action Complaint. In general, the consolidated complaint alleges that, during a class period commencing as of July 17, 2002 and ending April 2, 2003, the Company and individually named defendants misrepresented or failed to disclose certain factors, which they allege impacted the Companys business and anticipated revenue and earnings, all allegedly in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.
On June 16, 2004 the Court granted the Companys and the individual defendants Motion to Dismiss and ordered the Consolidated Class Action Complaint dismissed with prejudice against re-filing. On June 30, 2004, the Lead Plaintiff appealed the District Courts dismissal of the action to the United States Court of Appeals for the Eighth Circuit. The parties filed their appellate briefs and the issues were argued before the Eighth Circuit on January 13, 2005. The matter is now submitted to the Eighth Circuit for decision but the Company does not know when the Court of Appeals will rule on the appeal.
The Company believes that the District Court was correct in dismissing the consolidated complaint and that all the claims asserted in that complaint are without merit. In the event that the Court of Appeals reverses the District Courts dismissal, the Company intends to continue with its vigorous defense of those claims.
Item 4. Submission of Matters to a Vote of Security Holders
No matters were submitted to a vote of the shareholders of the Company during the fourth quarter of the fiscal year ended January 1, 2005.
17
Item 4A. Executive Officers of the Company
The following table sets forth the names, ages, positions and certain other information regarding the Companys executive officers as of March 9, 2005. Officers are elected annually and serve at the discretion of the Board of Directors.
Name | Age | Positions | ||
Neal L. Patterson
|
55 | Chairman of the Board of Directors and Chief Executive Officer | ||
|
||||
Clifford W. Illig
|
54 | Vice Chairman of the Board of Directors | ||
|
||||
Earl H. Devanny, III
|
53 | President | ||
|
||||
Paul M. Black
|
46 | Executive Vice President and Chief Operating Officer | ||
|
||||
Douglas M. Krebs
|
47 | Senior Vice President Cerner and General Manager of Cerner Europe, Middle East and Asia Pacific Organization | ||
|
||||
Marc G. Naughton
|
50 | Senior Vice President and Chief Financial Officer | ||
|
||||
Jeffrey A. Townsend
|
41 | Senior Vice President | ||
|
||||
Mike Valentine
|
36 | Senior Vice President and General Manager of U.S. Client Organization | ||
|
||||
Randy D. Sims
|
44 | Vice President, Chief Legal Officer and Secretary | ||
|
||||
Shellee K. Spring
|
39 | Vice President, Intellectual Property | ||
|
||||
Julia M. Wilson
|
42 | Vice President and Chief People Officer |
Neal L. Patterson has been Chairman of the Board of Directors and Chief Executive Officer of the Company for more than five years. Mr. Patterson also served as President of the Company from March of 1999 until August of 1999.
Clifford W. Illig has been a Director of the Company for more than five years. He also served as Chief Operating Officer of the Company for more than five years until October 1998 and as President of the Company for more than five years until March of 1999. Mr. Illig was appointed Vice Chairman of the Board of Directors in March of 1999.
Earl H. Devanny, III joined the Company in August of 1999 as President. Mr. Devanny also served as interim President of Cerner Southeast from January 2003 through July 2003. Prior to joining the Company, Mr. Devanny served as president of ADAC Healthcare Information Systems, Inc. Prior to joining ADAC, Mr. Devanny served as a Vice President of the Company from 1994 to 1997. Prior to that he spent seventeen years with IBM Corporation.
Paul M. Black joined the Company in March of 1994 as a Regional Vice President. He was promoted in June 1998 to Senior Vice President and Chief Sales Officer and to Executive Vice President in September of 2000. In January of 2003 Mr. Black was named Executive Vice President of the U.S. Client Organization. In February of 2005 Mr. Black was named Chief Operating Officer. Prior to joining the Company, he spent twelve years with IBM Corporation.
Douglas M. Krebs joined the Company in June 1994 as a Regional Vice President. He was promoted to Senior Vice President and Area Manager in April 1999. In February 2000, Mr. Krebs was appointed as President of Cerner Global. Prior to joining Cerner, he spent fifteen years with IBM Corporation.
18
Marc G. Naughton joined the Company in November 1992 as Manager of Taxes. In November 1995 he was named Chief Financial Officer and in February 1996 he was promoted to Vice President. He was promoted to Senior Vice President in March 2002.
Jeffrey A. Townsend joined the Company in June 1985. Since that time he has held several positions in the Intellectual Property Organization and was promoted to Vice President in February 1997. He was appointed Chief Engineering Officer in March 1998. He was promoted to Senior Vice President in March 2001.
Mike Valentine joined the Company in December 1998 as Director of Technology. He was promoted to Vice President in 2000 and to President of Cerner Mid America in January of 2003. In February 2005, he was named General Manager of the U.S. Client Organization and was promoted to Senior Vice President in March 2005. Prior to joining the Company, Mr. Valentine was with Accenture Consulting.
Randy D. Sims joined the Company in March 1997 as Vice President and Chief Legal Officer. Prior to joining the Company, Mr. Sims worked at Farmland Industries, Inc. for three years where he served most recently as Associate General Counsel. Prior to Farmland, Mr. Sims was in-house legal counsel at The Marley Company for seven years, holding the position of Assistant General Counsel when he left to join Farmland.
Shellee K. Spring joined the Company in September 1989 as a systems engineer. Since that time, she has held several positions throughout the Company including positions in the Consulting, Sales and Intellectual Property Organizations. She was promoted to Vice President in March 1999.
Julia M. Wilson joined the Company in November 1995. Since that time, she has held several positions in the Functional Group organization. She was promoted to Vice President and to the position of Chief People Officer in August 2003.
19
PART II
Item 5. Market for the Registrants Common Stock and Related Security Holder Matters
The Companys common stock trades on
The NASDAQ Stock Market
®
under the symbol CERN.
The following table sets forth the high, low and last sales prices for the fiscal quarters of 2004
and 2003 as reported by
The NASDAQ National Market System
. These quotations represent prices
between dealers and do not include retail mark-up, mark-down or commissions, and do not necessarily
represent actual transactions.
At January 31, 2005, there were approximately 1,600 owners of record
.
To date, the Company
has paid no dividends and it does not intend to pay dividends in the foreseeable future.
Management believes it is in the shareholders best interest to reinvest funds in the operation of
the business.
Item 6. Selected Financial Data
20
21
Introduction
Cerner Corporation (Cerner or the Company) is headquartered in North Kansas City, Missouri.
Cerner derives revenue by selling, implementing and supporting software solutions and hardware that
gives healthcare providers secure access to clinical, administrative and financial data in real
time, allowing them to improve the quality, safety and efficiency in the delivery of healthcare.
Cerner implements these solutions as stand-alone, combined or enterprise-wide systems.
Cerner
solutions can be managed by the Companys clients or in Cerners data center via a managed services
model.
Results Overview
The Company delivered strong results in 2004. Total new business bookings, which reflect the value
of contracts for software, hardware, services and managed services (hosting of software in the
Companys data center), were $917,367,000 in 2004, an increase of 13% compared to $811,258,000 in
2003.
Total revenues for 2004 were $926,356,000, an increase of 10% compared to 2003. The revenue
composition was $351,861,000 in system sales, $241,439,000 in support and maintenance, $300,975,000
in services and $32,081,000 in reimbursed travel. Systems sales revenue, which includes licensed
software, sub-licensed software, hardware, and subscriptions, grew 6% in 2004. Services revenue,
which includes managed services, grew 13% for the year. Support and maintenance revenue grew 15%
for the year.
The Companys solid bookings drove a 27% year-over-year increase in contract backlog, which
reflects new business bookings that have not yet been recognized as revenue, and ended the year at
$1,191,170,000. Backlog grew faster than revenue again in 2004 as the Company continued to
experience strong growth in managed services and subscription bookings, which are recognized as
revenue over a longer period of time than other types of bookings, such as software and hardware.
Collectively, managed services and subscription bookings accounted for about 24% of total bookings
margin in 2004 compared to approximately 20% in 2003 and 15% in 2002. This continued shift in mix
provides greater visibility of revenue going into 2005 and beyond.
The strong growth in managed services bookings contributed to a decline in hardware bookings and
hardware revenue in 2004 as clients electing managed services do not need to make the upfront
hardware purchase that they would make in a transaction that does not include managed services. As
a result, hardware revenue declined 18% in 2004 compared to 2003. Licensed software revenue grew
at a strong rate of 14% in 2004
,
but this growth was partially offset by the decline in hardware
revenue, resulting in lower system sales growth of 6% for 2004. Despite the near-term impact on
system sales, the Company views this mix shift favorably because the higher level of managed
services bookings improves the visibility of future revenue streams.
Net earnings increased from $42,791,000 in 2003 to $64,648,000 in 2004. Included in 2004 results
are an adjustment in the third quarter of 2004 related to a prior period vacation pay accrual (see
Note 14 to consolidated financial statements) that reduced net earnings by $2,076,000, net of
$1,270,000 of tax, and a gain on the sale of Zynx Health Incorporated in the first quarter of 2004
that increased net earnings by $1,826,000, net of $1,197,000 of tax. Excluding these two items,
2004 net earnings would have been $250,000 higher, or $64,898,000.
The increase in net earnings was driven by revenue growth and margin expansion. Operating margins
were 12.0% (12.4% prior to the vacation accrual adjustment) for 2004 compared to 9.3% in 2003.
Going forward, management believes the Company can continue to increase operating margins by
expanding margins on services, leveraging investments in research and development, and controlling
sales, general and administrative spending.
22
The Companys operational performance was also very strong in 2004. The Company brought a record
1,079
Cerner Millennium
solutions live in 2004, bringing the cumulative number of solutions
implemented to more than 3,700 at nearly 750 client facilities. These results included significant
progress at implementing computerized physician order entry (CPOE), which is the application
generating the highest level of industry attention.
The Companys strong operational performance is also reflected in its cash flow results. In 2004,
the Company generated $168,304,000 of cash flow from operations, compared to $134,150,000 in 2003.
Free cash flow, defined as operating cash flow less capital expenditures and capitalized software,
was $52,902,000 in 2004 compared to ($8,169,000) in 2003.
Healthcare Information Technology Market
The Company believes the market for healthcare information technology remains strong. The
healthcare information technology industry, and Cerner specifically, continues to benefit from the
focus healthcare providers have placed on using technology to drive major patient safety and
quality initiatives into their organizations with the ultimate goal of becoming completely digital
or paperless. In addition, the Company continues to benefit from its clients increased desire to
have a common architecture spanning clinical, management and financial solutions.
In many ways, the Company believes 2004 was a defining year for the healthcare information
technology industry. President Bush began the year by proclaiming in his State of the Union
Address that we can avoid dangerous medical mistakes, reduce costs and improve care by
computerizing health records. The President also established a goal for every American to have a
personal health record within the next 10 years, and he reaffirmed that goal in his 2005 State of
the Union Address. In the spring of 2004, the President created a sub-cabinet position at the
Department of Health and Human Services (HHS) to spearhead this effort. In the summer of 2004,
Senator Hillary Clinton and Majority Leader Bill Frist took to the pages of the Washington Post to
opine in bipartisan fashion that information technology is central to solving the healthcare
crisis. And as the Democratic and Republican parties laid out their agendas in January of 2005 for
the 109th Congress, both signaled a strong commitment to healthcare information technology.
Finally, 2004 saw more widespread adoption of pay-for-performance compensation systems for both
hospitals and physician offices. Employers such as General Motors, Delta Airlines, UPS, Verizon,
General Electric, and Boeing led the way both at the company level and through The Leapfrog Groups
standards. And in February of 2005, the Center for Medicare and Medicaid Services (CMS) announced
the first ever Medicare pay-for-performance initiative for doctors.
In summary, 2004 was an exciting year of increased focus on healthcare information technology.
Although no assurances can be provided, management believes, and recent events suggest, that this
momentum could continue.
Results of Operations
Year Ended January 1, 2005, Compared to Year Ended January 3, 2004
The Companys revenues increased 10% to $926,356,000 in 2004 from $839,587,000 in 2003. The
Company had net earnings of $64,648,000 in 2004 compared to $42,791,000 in 2003. Included in 2004
net earnings are an adjustment in the third quarter of 2004 related to a prior period vacation pay
accrual that reduced net earnings by $2,076,000, net of $1,270,000 of tax, and a gain on the sale
of Zynx Health Incorporated, in the first quarter of 2004 that increased net earnings by
$1,826,000, net of $1,197,000 of tax. Excluding these two items, 2004 net earnings would have been
$250,000 higher, or $64,898,000.
Revenues
- In 2004, revenues increased due to an increase in system sales, support of installed
systems and an increase in services. Support, maintenance and service revenues increased 14% to
$542,414,000 in 2004 from $476,795,000 in 2003. Support and maintenance revenues were $241,439,000
and $209,876,000 in 2004 and 2003, respectively. Services revenues were $300,975,000
23
and $266,918,000 in 2004 and 2003, respectively. Included in support, maintenance and service
revenues are support and maintenance of software and hardware, managed services and professional
services, excluding installation. The increase in support and maintenance revenue was due
primarily to the increase in the Companys installed and converted client base, that was driven by
bringing a record number of
Cerner Millennium
solutions live in 2003 and 2004. The increase in
services revenue was driven by increased professional services billable hours and a strong increase
in managed services.
System sales increased 6% to $351,861,000 in 2004 from $332,349,000 in 2003. Included in system
sales are revenues from the sale of software, hardware and sublicensed software. This increase is
due primarily to an increase in license software sales that was partially offset by declines in
hardware sales.
At January 1, 2005, the Company had $1,191,170,000 in contract backlog and $347,662,000 in support
and maintenance backlog, compared to $938,221,000 in contract backlog and $312,887,000 in support
and maintenance backlog at the end of 2003.
Cost of Revenues
- The cost of revenues includes the cost of reimbursed travel expense, third party
consulting services and subscription content, computer hardware and sublicensed software purchased
from computer and software manufacturers for delivery to clients. It also includes the cost of
hardware maintenance and sublicensed software support subcontracted to the manufacturers. The cost
of revenues was 21% of total revenues in 2004, and 23% of total revenues in 2003. Such costs, as a
percent of revenues, typically have varied as the mix of revenue (software, hardware, services and
support) components carrying different margin rates changes from period to period. The decrease in
the cost of revenue as a percent of total revenues resulted principally from a decrease in the
percent of revenue from computer hardware and sublicensed software, which carry a higher cost of
revenue percentage. The Company believes this trend could continue because of strong demand for
its managed service offering, which results in lower hardware sales because the client does not
purchase hardware when it chooses this offering.
Sales and Client Service
- Sales and client service expenses include salaries of client service
personnel, communications expenses and unreimbursed travel expenses. Also included are sales and
marketing salaries, travel expenses, tradeshow costs and advertising costs. These expenses as a
percent of total revenues were 41% and 42% in 2004 and 2003, respectively. The increase in total
sales and client service expenses to $383,628,000 in 2004 from $352,728,000 in 2003 is primarily
due to an increase in personnel and personnel related expenses. The decrease in this spending as a
percent of total revenue reflects the Companys ability to get better utilization of its resources
and leverage this spending over a larger revenue stream.
Software Development
- Software development expenses include salaries, documentation and other
direct expenses incurred in software development and amortization of software development costs.
Total expenditures for software development, including both capitalized and noncapitalized
portions, for 2004 and 2003 were $188,264,000 and $179,999,000, respectively. These amounts
exclude amortization. Capitalized software costs were $58,912,000 and $58,736,000 for 2004 and
2003, respectively. The increase in aggregate expenditures in software development in 2004 is due
to continued development of
Cerner Millennium
solutions.
General and Administrative
- General and administrative expenses include salaries for corporate,
financial and administrative staffs, utilities, communications expenses and professional fees.
These expenses as a percent of total revenues were 7% in both 2004 and 2003. Total general and
administrative expenses were $63,327,000 and $58,236,000 for 2004 and 2003, respectively. General
and administrative expenses for 2004 include a prior period adjustment to increase vacation pay
accrual of $3,346,000. Excluding the adjustment to increase vacation pay accrual, general and
administrative expenses as a percent of revenues were 6% in 2004.
Interest Expense, Net
-
Interest income was $3,022,000 in 2004 compared to $1,219,000 in 2003.
This increase is due primarily to higher interest rates, and a higher cash balance fed by cash
collections. Interest expense was $9,174,000 in 2004 compared to $8,236,000 in 2003.
24
Other Income, Net
- Other income increased from $142,000 in 2003 to $2,608,000 in 2004. This
increase is due primarily to a gain on the sale of Zynx Health Incorporated. Also included in
other income are revenues from office space leased to third parties.
Operations by Segment
In 2003, the Company organized geographically. The Companys six geographic business segments are:
Great Lakes, Mid-America, North Atlantic, Southeast, West and Global. Revenues are derived
primarily from the sale of clinical, financial and administrative information systems and
solutions. The cost of revenues includes the cost of third party consulting services, computer
hardware and sublicensed software purchased from computer and software manufacturers for delivery
to clients. It also includes the cost of hardware maintenance and sublicensed software support
subcontracted to the manufacturers. Operating expenses incurred by the geographic business
segments consist of sales and client service expenses including salaries of sales and client
service personnel, communications expenses and unreimbursed travel expenses. Performance of the
segments is assessed at the operating earnings level and, therefore, the segment operations have
been presented as such. Other includes revenues not generated by the operating segments and
expenses such as software development, marketing, general and administrative and depreciation that
have not been allocated to the operating segments. The Company does not track assets by
geographical business segment.
The following table presents a summary of the operating information for 2004 and 2003 (in
thousands):
Operating earnings in the Great Lakes segment increased 9% for the year ended January 1, 2005
compared to the year ended January 3, 2004. Total revenues increased 2% in 2004 compared to 2003.
The increase in total revenues is due primarily to strong increases in licensed software and
support revenues that were largely offset by a decrease in hardware and professional services
revenues in 2004 compared to 2003. Costs of revenues were 19% and 24% of total revenues of the
Great Lakes segment for 2004 and 2003, respectively. The decrease in the cost of revenues as a
percent of revenue is due primarily to lower hardware sales in 2004 as compared to 2003. Costs of
revenues, as a percent of revenues, typically have varied as the mix of revenue (software,
hardware, maintenance, support, services and reimbursed travel) components carrying different
margin rates changes from period to period.
25
Operating earnings in the Mid-America segment increased 37% for the year ended January 1, 2005
compared to the year ended January 3, 2004. Total revenues increased 25% in 2004 compared to 2003.
The increase in total revenues is due primarily to a strong increase in licensed software and
professional services revenues in 2004 compared to 2003. Costs of revenues were 16% and 22% of
total Mid-America segment revenues for 2004 and 2003, respectively. The decrease in the cost of
revenues as a percent of revenue is due primarily to lower hardware sales in 2004 as compared to
2003.
Operating earnings in the North Atlantic segment increased 27% for the year ended January 1, 2005
compared to the year ended January 3, 2004. Total revenues increased 20% in 2004 compared to 2003.
The increase in revenues is due primarily to an increase in licensed software and professional
services revenues in 2004 compared to 2003. Costs of revenues were 23% and 25% of total North
Atlantic segment revenues for 2004 and 2003, respectively.
Operating earnings in the Southeast segment increased 6% for the year ended January 1, 2005
compared to the year ended January 3, 2004. Total revenues increased 2% in 2004 compared to 2003.
Costs of revenues were 24% and 28% of total Southeast segment revenues for 2004 and 2003,
respectively. The increase in total revenues is due primarily to strong increases in licensed
software and support revenues that were largely offset by a decrease in hardware and professional
services in 2004 compared to 2003.
Operating earnings in the West decreased 16% for the year ended January 1, 2005 compared to the
year ended January 3, 2004. Total revenues decreased 7% in 2004 compared to 2003. The decrease in
total revenues is due primarily to a decrease in licensed software in 2004 compared to 2003. Costs
of revenues were 19% and 17% of total West segment revenues for 2004 and 2003, respectively.
Operating expenses increased 20% in 2004 compared to 2003, due primarily to an increase in
personnel related expenses.
Operating earnings in the Global segment increased 245% for the year ended January 1, 2005 compared
to the year ended January 3, 2004. Total revenues increased 19% in 2004 compared to 2003. The
increase in total revenues is due primarily to an increase in professional services in 2004
compared to 2003. Operating expenses increased 7% in 2004 compared to 2003. These increases are
due primarily to an increased presence in the global market.
Operating losses in Other increased 9% for the year ended January 1, 2005 compared to the year
ended January 3, 2004. This increase is due to an increase in total costs and expenses of 11% in
2004 compared to 2003. The increase in operating expenses is due to an increase in expenses such
as software development, marketing, general and administrative and depreciation in 2004 compared to
2003.
Year Ended January 3, 2004, Compared to Year Ended December 28, 2002
The Companys revenues increased 8% to $839,587,000 in 2003 from $780,262,000 in 2002. The Company
had net earnings of $42,791,000 in 2003 compared to $48,022,000 in 2002. Operating results for
2002, as described below, included a gain on the sale of available-for-sale securities and a charge
for the impairment of investments, and a change in accounting principle for goodwill. The decrease
in net earnings is due primarily to a higher increase in expenses than revenue compared to the
prior year. As discussed above, revenue increased less than the Company expected because of the
decrease in new contract bookings in the first quarter of 2003 and the shift in bookings mix to
more managed services and subscription bookings which are recognized as revenue over longer periods
of time. The increase in expenses was driven primarily by continued investments in the Companys
development of software and by sales and client services expenses. Expenses also increased because
the Companys 2003 fiscal year consisted of 53 weeks compared to 52 weeks in 2002.
Revenues
- In 2003, revenues increased due to an increase in support of installed systems and an
increase in services. Support, maintenance and service revenues increased 14% to $476,795,000 in
2003 from $419,578,000 in 2002. Support and maintenance revenues were $209,877,000 and
$171,238,000 in 2003 and 2002, respectively. Services revenues were $266,918,000 and $248,340,000
in 2003 and 2002, respectively. Included in support, maintenance and service revenues are support
and
26
maintenance of software and hardware and professional services, excluding installation. This
increase in support and maintenance revenue was due primarily to the increase in the Companys
installed and converted client base, that was driven by bringing a record number of
Cerner
Millennium
solutions live in 2002 and 2003. The increase in services revenue was driven primarily
by an increase in revenue from managed services, which increased $20,000,000 to $34,000,000 as the
Company continued to experience high levels of demand for hosting solutions in its data center.
System sales were $332,349,000 in 2003 compared to $332,274,000 in 2002. Included in system sales
are revenues from the sale of software, hardware and sublicensed software. System sales were flat
because of the aforementioned first quarter bookings shortfall and because of a shift in the mix of
bookings during the year.
At January 3, 2004, the Company had $938,221,000 in contract backlog and $312,887,000 in support
and maintenance backlog, compared to $732,719,000 in contract backlog and $269,153,000 in support
and maintenance backlog at the end of 2002.
Cost of Revenues
- The cost of revenues includes the cost of reimbursed travel expense, third party
consulting services and subscription content, computer hardware and sublicensed software purchased
from computer and software manufacturers for delivery to clients. It also includes the cost of
hardware maintenance and sublicensed software support subcontracted to the manufacturers. The cost
of revenues was 23% of total revenues in 2003, and 24% of total revenues in 2002. Such costs, as a
percent of revenues, typically have varied as the mix of revenue (software, hardware, services and
support) components carrying different margin rates changes from period to period. The decrease in
the cost of revenue as a percent of total revenues resulted principally from a decrease in the
percent of revenue from computer hardware and sublicensed software, which carry a higher cost of
revenue percentage.
Sales and Client Service
- Sales and client service expenses include salaries of client service
personnel, communications expenses and unreimbursed travel expenses. Also included are sales and
marketing salaries, travel expenses, tradeshow costs and advertising costs. These expenses as a
percent of total revenues were 42% and 41% in 2003 and 2002, respectively. The increase in total
sales and client service expenses is attributable to the cost of marketing of solutions. Expenses
also increased due to the extra week in the 2003 fiscal year as described above.
Software Development
- Software development expenses include salaries, documentation and other
direct expenses incurred in software development and amortization of software development costs.
Total expenditures for software development, including both capitalized and noncapitalized
portions, for 2003 and 2002 were $179,999,000 and $149,985,000, respectively. These amounts
exclude amortization. Capitalized software costs were $58,736,000 and $49,984,000 for 2003 and
2002, respectively.
General and Administrative
- General and administrative expenses include salaries for corporate,
financial and administrative staffs, utilities, communications expenses and professional fees.
These expenses as a percent of total revenues were 7% and 6% in 2003 and 2002, respectively.
Interest Expense, Net
-
Interest income was $1,219,000 in 2003 compared to $1,080,000 in 2002.
This increase is due primarily to an increase in invested cash in 2003 compared to 2002. Interest
expense was $8,236,000 in 2003 compared to $6,635,000 in 2002. This increase is due primarily to
the increase in debt. On December 20, 2002, the Company completed a $60,000,000 private placement
of debt pursuant to a Note Agreement dated December 15, 2002.
Other Income, Net
- Other income increased to $142,000 in 2003 from $87,000 in 2002. Included in
other revenues are revenues from office space leased to third parties.
Gain (Loss) on Sale of Investment
In December 2002, the Company exercised 1,048,783 warrants of
WebMD with an exercise price of $3.08 and a cost basis and carrying value of $4,146,000. The
warrants were scheduled to expire on January 26, 2003. In December 2002, the Company sold
1,048,783 shares of WebMD for $8,242,000. Accordingly, the Company recorded an investment gain of
$527,000, net of $342,000 in tax, as a result of the exercise of the warrants and the sale of the
shares. In the second
27
quarter of 2002, the Company sold 14,820,527 shares of WebMD for $90,119,000. Accordingly, the
Company recorded an investment gain of $2,736,000, net of $1,572,000 in tax, as a result of the
sale.
Impairment of Investment
The Companys policy is to review declines in fair value of its
marketable equity securities for declines that may be other than temporary. Based on events
occurring in the fourth quarter of 2002, the Company recorded a charge of $6,281,000, net of tax of
$3,623,000, for the impairment of various investments in non-publicly traded securities. The
charge is primarily related to a $3,464,000, net of tax, write down of the Companys investment in
Protocare, Inc. a non-publicly traded company.
Income Taxes
- The Companys effective tax rate was 39.9% in 2003 and 39.4% in 2002. As a result
of a decrease in net income from 2002 to 2003, the impact of permanent differences increased the
Companys effective tax rate.
Accounting Change
- Effective December 30, 2001, the Company adopted the provisions of Statement of
Financial Accounting Standards (SFAS) No. 142, Goodwill and Other Intangible Assets. As a
result, goodwill and intangible assets with indefinite lives are no longer amortized but are
evaluated for impairment annually or whenever there is an impairment indicator. All goodwill is
assigned to a reporting unit, where it is subject to an impairment test based on fair value. The
Company completed its transitional review of the Companys goodwill values in the second quarter of
2002. As a result of this review, the Company determined that goodwill arising from the
acquisition of Mitch Cooper and Associates was impaired due to declining demand and margins in this
business. Mitch Cooper and Associates was a supply chain re-engineering consulting practice. The
impairment charge to reflect this goodwill at fair value was $786,000, net of tax, and is reflected
as a cumulative effect of a change in accounting principle as of the beginning of 2002. The
Company used a discounted cash flow analysis to determine the fair value of the reporting units.
Liquidity and Capital Resources
The Companys liquidity is influenced by many factors, including the amount and timing of the
Companys revenues, its cash collections from its clients and the amounts the Company invests in
software development, acquisitions and capital expenditures.
The Companys principal source of liquidity is its cash and cash equivalents. The majority of the
Companys cash and cash equivalents consist of U.S. Government Federal Agency Securities,
short-term marketable securities and overnight repurchase agreements. At January 1, 2005 the
Company had cash and cash equivalents of $189,784,000 and working capital of $310,229,000 compared
to cash and cash equivalents of $121,839,000 and working capital of $246,412,000 at January 3,
2004.
The Company generated cash of $168,304,000, $134,150,000 and $36,906,000 from operations in 2004,
2003 and 2002, respectively. Cash flow from operations increased in 2004 due primarily to
increased collections of receivables, improved payment terms and record level conversions. The
Company has periodically provided long-term financing options to creditworthy clients through third
party financing institutions and typically has directly provided extended payment terms from
contract date. Some of these payment streams have been assigned on a non-recourse basis to third
party financing institutions. The Company has provided its usual and customary performance
guarantees to the third party financing institutions in connection with its on-going obligations
under the client contract. During 2004 and 2003, the Company generated cash flow from third party
client financing arrangements and non-recourse payment assignments aggregating $53,319,000 and
$58,654,000, respectively. Days sales outstanding increased from 103 days at the end of 2003 to
104 days at the end of 2004. Revenues provided under support and maintenance agreements represent
recurring cash flows. Support and maintenance revenues increased 15% in 2004 and 23% in 2003, and
the Company expects these revenues to continue to grow as the base of installed systems grows.
Cash used in investing activities consisted primarily of capitalized software development costs of
$58,912,000 and $58,736,000 and purchases of capital equipment, land and buildings of $56,490,000
and $83,583,000 in 2004 and 2003, respectively. The Company completed acquisitions of businesses
for
28
$1,957,000 and $6,380,000, net of cash received, in 2004 and 2003, respectively. The Company
completed the sale of Zynx Health Incorporated in 2004 for $12,000,000.
The Companys financing activities for 2004 primarily consisted of repayment of debt of $24,879,000
and the proceeds from the exercise of stock options of $25,717,000. Financing activities for 2003
primarily consisted of the repayment of long term debt of $13,238,000, the purchase of treasury
stock of $5,930,000 and the proceeds from the exercise of stock options of $6,703,000.
Prior to May 2002, the Company had a loan agreement with a bank that provided for a current
revolving line of credit for working capital purposes. In May 2002, the Company expanded its
credit facility by entering into an unsecured revolving credit agreement with a group of banks led
by U.S. Bank. The new credit facility increased the amount the Company may borrow from $45,000,000
to $90,000,000. The fee rate on the new facility is approximately the same as the prior facility.
The revolving line of credit is unsecured and requires monthly payments of interest only. Interest
is payable at the Companys option at a rate based on prime (5.25% at January 1, 2005) or LIBOR
(2.4% at January 1, 2005) plus 2%. The interest rate may be reduced by up to 1.15% if certain net
worth ratios are maintained. The agreement contains certain net worth, debt levels and fixed
charge coverage covenants and provides certain restrictions on the Companys ability to borrow,
incur liens, sell assets and pay dividends. A commitment fee of 3/10% to 1/2% is payable quarterly
based on the usage of the revolving line of credit. The revolving line of credit matures on May
31, 2007. The Company was in compliance with all covenants at January 1, 2005. At January 1,
2005, the Company had no outstanding borrowings under this agreement and had $90,000,000 available
for working capital purposes. On January 10, 2005, the Company drew down $35,000,000 from its
revolving line of credit in connection with the acquisition of the
medical business division of VitalWorks, Inc. (See Note 2 to the consolidated financial statements.)
In December 2002, the Company completed a $60,000,000 private placement of debt pursuant to a Note
Agreement. The Series A Senior Notes, with a $21,000,000 principal amount at 5.57%, are payable in
three equal annual installments beginning in December 2006. The Series B Senior notes, with a
$39,000,000 principal amount at 6.42%, are payable in four equal annual installments beginning
December 2009. The proceeds were used to repay the outstanding amount under the bank loan
agreement and for general corporate purposes. The Note Agreement contains certain net worth and
fixed charge coverage covenants and provides certain restrictions on the Companys ability to
borrow, incur liens, sell assets and pay dividends. The Company was in compliance with all
covenants at January 1, 2005.
In April 1999, the Company completed a $100,000,000 private placement of debt pursuant to a Note
Agreement. The Series A Senior Notes, with a $60,000,000 principal amount at 7.14%, are payable in
five equal annual installments beginning in April 2002. The Series B Senior Notes, with a
$40,000,000 principal amount at 7.66%, are payable in six equal annual installments beginning April
2004. The proceeds were used to retire the Companys existing $30,000,000 of debt, and the
remaining funds were used for capital improvements and to strengthen the Companys cash position.
The Note Agreement contains certain net worth, current, and fixed charge coverage covenants and
provides certain restrictions on the Companys ability to borrow, incur liens, sell assets and pay
dividends. The Company was in compliance with all covenants at January 1, 2005.
The Company believes that its present cash position, together with cash generated from operations
and the line of credit, will be sufficient to meet anticipated cash requirements during 2005.
The following table represents a summary of the Companys contractual obligations and commercial
commitments as of January 1, 2005, except short-term purchase order commitments arising in the
ordinary course of business.
29
The effects of inflation on the Companys business during 2004, 2003 and 2002 were not
significant.
Recent Accounting Pronouncements
In December 2004, the FASB issued Statement of Financial Accounting Standards (SFAS) No. 123
(revised 2004), Share Based Payments (SFAS No. 123(R)) which replaces SFAS 123, Accounting for
Stock-Based Compensation, and supersedes APB Opinion No. 25, Accounting for Stock Issued to
Employees. SFAS No. 123(R) addresses the accounting for share-based payments transactions with
employees and other third parties, eliminates the ability to account for share-based compensation
transactions using APB 25 and requires that the compensation costs relating to such transactions be
recognized in the consolidated statement of income. The new standard is effective in the first
interim period beginning after June 15, 2005. The Company is currently assessing the impact that
the Statement may have on its consolidated financial statements.
Critical Accounting Policies
The Company believes that there are several accounting policies that are critical to understanding
the Companys historical and future performance, as these policies affect the reported amount of
revenue and other significant areas involving managements judgments and estimates. These
significant accounting policies relate to revenue recognition, software development,
concentrations, allowance for doubtful accounts and potential impairments of goodwill. These
policies and the Companys procedures related to these policies are described in detail below and
under specific areas within this Management Discussion and Analysis or Financial Condition and
Results of Operations. In addition, Note 1 to the consolidated financial statements expands upon
discussion of the Companys accounting policies.
Revenue Recognition
The Company recognizes its multiple element arrangements, including software and software-related
services, using the residual method under SOP 97-2, Software Revenue Recognition, as amended by
SOP No. 98-4, SOP 98-9 and clarified by Staff Accounting Bulletins (SAB) 101 Revenue Recognition
in Financial Statements and SAB No. 104 Revenue Recognition and Emerging Issues Task Force 00-21
Accounting for Revenue Arrangements with Multiple Deliverables (EITF 00-21). Key factors in
the Companys revenue recognition model are managements assessments that installation services are
essential to the functionality of the Companys software whereas implementation services are not.
If the Companys business model were to change such that implementation services became essential
to the functionality of the Companys software, the period of time over which the Companys
licensed software revenue were to be recognized would lengthen. The Company generally recognizes
revenue from the sale of its licensed software over two key milestones, delivery and installation,
based on percentages that reflect the underlying effort from planning to installation.
Additionally, if the time to achieve the Companys delivery and installation milestones for its
licensed software were to be accelerated or decelerated, its milestones would be adjusted and the
timing of revenue recognition for its licensed software could materially change.
30
Software Development Costs
Costs incurred internally in creating computer software solutions are expensed until technological
feasibility has been established upon completion of a detailed program design. Thereafter, all
software development costs are capitalized and subsequently reported at the lower of amortized cost
or net realizable value. Capitalized costs are amortized based on current and expected future
revenue for each software solution with minimum annual amortization equal to the straight-line
amortization over the estimated economic life of the software solution. The Company is amortizing
capitalized costs over five years.
The Company expects that major software information systems companies, large information technology
consulting service providers and systems integrators and others specializing in the healthcare
industry may offer competitive products or services. The pace of change in the healthcare
information systems market is rapid and there are frequent new product introductions, product
enhancements and evolving industry standards and requirements. As a result, the capitalized
software solutions may become less valuable or obsolete and could be subject to impairment.
Concentrations
Substantially all of the Companys cash and cash equivalents and short-term investments, are held
at three major U.S. financial institutions. The majority of the Companys cash equivalents consist
of U.S. Government Federal Agency Securities, short-term marketable securities and overnight
repurchase agreements. Deposits held with banks may exceed the amount of insurance provided on
such deposits. Generally these deposits may be redeemed upon demand and, therefore, bear minimal
risk.
Substantially all of the Companys clients are integrated delivery networks, hospitals and other
healthcare related organizations. If significant adverse macro-economic factors were to impact
these organizations it could materially adversely affect the Company. The Companys access to
certain software and hardware components is dependent upon single and sole source suppliers. The
inability of any supplier to fulfill supply requirements of the Company could affect future
results.
Allowance for Doubtful Accounts
If the creditworthiness of the Companys clients were to weaken or the Companys collections
results relative to historical experience were to decline, it could have a material adverse impact
on operations and cash flows.
Goodwill
The Company accounts for its goodwill under the provisions of Statement of Financial Accounting
Standards (SFAS) No. 142, Goodwill and Other Intangible Assets. As a result, goodwill and
intangible assets with indefinite lives are no longer amortized but are evaluated for impairment
annually or whenever there is an impairment indicator. All goodwill is assigned to a reporting
unit, where it is subject to an impairment test based on fair value. The Company completed its
transitional review of the Companys goodwill values in the second quarter of 2002. As a result of
this review, the Company determined that goodwill arising from the acquisition of Mitch Cooper and
Associates was impaired due to declining demand and margins in this business. Mitch Cooper and
Associates was a supply chain re-engineering consulting practice. The impairment charge to reflect
this goodwill at fair value was $786,000, net of tax, and is reflected as a cumulative effect of a
change in accounting principle as of the beginning of 2002. The Company again assessed its
goodwill for impairment in the second quarters of 2004 and 2003 and concluded that no goodwill was
impaired. The Company used a discounted cash flow analysis to determine the fair value of the
reporting units for all periods. The Company completed five acquisitions and one divestiture
subsequent to June 30, 2001, which resulted in approximately $35 million of goodwill that was not
amortized in accordance with SFAS 142. Goodwill amounted to $54,600,000 and $51,573,000 at January
1, 2005 and January 3, 2004, respectively. If future, anticipated cash flows from the Companys
reporting units, that recognized goodwill, do not materialize as expected the Companys goodwill
could be impaired, which would result in significant write-offs.
31
Factors that may Affect Future Results of Operations, Financial Condition or Business
Statements made in this report, the Annual Report to Shareholders in which this report is made a
part, other reports and proxy statements filed with the Securities and Exchange Commission,
communications to shareholders, press releases and oral statements made by representatives of the
Company that are not historical in nature, or that state the Companys or managements intentions,
hopes, beliefs, expectations or predictions of the future, may constitute forward-looking
statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as
amended (the Exchange Act). Forward-looking statements can often be identified by the use of
forward-looking terminology, such as could, should, will, intended, continue, believe,
may, expect, hope, anticipate, goal, forecast, plan, guidance or estimate or the
negative of these words, variations thereof or similar expressions. Forward-looking statements are
not guarantees of future performance or results. They involve risks, uncertainties and
assumptions. It is important to note that any such performance and actual results, financial
condition or business, could differ materially from those expressed in such forward-looking
statements. Factors that could cause or contribute to such differences include, but are not
limited to, those discussed below as well as those discussed elsewhere herein or in other reports
filed with the Securities and Exchange Commission. Other unforeseen factors not identified herein
could also have such an effect. The Company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events
or changes in future operating results, financial condition or business over time.
Quarterly Operating Results May Vary
The Companys quarterly operating results have
varied in the past and may continue to vary in future periods, including, variations from guidance,
expectations or historical results or trends. Quarterly operating results may vary for a number of
reasons including accounting policy changes mandated by regulating entities, demand for the
Companys software solutions and services, the Companys long sales cycle, potentially long
installation and implementation cycles for these larger, more complex and costlier systems and
other factors described in this section and elsewhere in this report. As a result of healthcare
industry trends and the market for the Companys
Cerner Millennium
solutions, a large percentage of
the Companys revenues are generated by the sale and installation of larger, more complex and
costlier systems. The sales process for these systems is lengthy and involves a significant
technical evaluation and commitment of capital and other resources by the client. Sales may be
subject to delays due to changes in clients internal budgets, procedures for approving large
capital expenditures, competing needs for other capital expenditures, availability of personnel
resources and by actions undertaken by competitors. Delays in the expected sale or installation
of these large contracts may have a significant impact on the Companys anticipated quarterly
revenues and consequently its earnings, since a significant percentage of the Companys expenses
are relatively fixed.
The Company recognizes revenue upon the completion of standard milestone conditions and the amount
of revenue recognized in any quarter depends upon the Companys and the clients ability to meet
these project milestones. Delays in meeting these milestone conditions or modification of the
contract relating to one or more of these systems could result in a shift of revenue recognition
from one quarter to another and could have a material adverse effect on results of operations for a
particular quarter. The Companys revenues from system sales historically have been lower in the
first quarter of the year and greater in the fourth quarter of the year, primarily as a result of
the clients year-end efforts to make all final capital expenditures for the then current year.
Stock Price May Be Volatile
The trading price of the Companys common stock may be
volatile. The market for the Companys common stock may experience significant price and volume
fluctuations in response to a number of factors including actual or anticipated quarterly
variations in operating results, rumors about the Companys performance or software solutions,
changes in expectations of future financial performance or changes in estimates of securities
analysts, governmental regulatory action, healthcare reform measures, client relationship
developments, changes occurring in the securities markets in general and other factors, many of
which are beyond the Companys control. As a matter of policy, the Company does not generally
comment on rumors.
32
Furthermore, the stock market in general, and the market for software and healthcare and
information technology companies in particular, has experienced extreme volatility that often has
been unrelated to the operating performance of particular companies. These broad market and
industry fluctuations may adversely affect the trading price of the Companys common stock,
regardless of actual operating performance.
Changes in the Healthcare Industry
The healthcare industry is highly regulated and is
subject to changing political, economic and regulatory influences. For example, the Balanced
Budget Act of 1997 (Public Law 105-32) contained significant changes to Medicare and Medicaid and
had an impact for several years on healthcare providers ability to invest in capital intensive
systems. In addition, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) is
having a direct impact on the healthcare industry by requiring identifiers and standardized
transactions/code sets and necessary security and privacy measures in order to ensure the
protection of patient health information. These factors affect the purchasing practices and
operation of healthcare organizations. Federal and state legislatures have periodically considered
programs to reform or amend the U.S. healthcare system at both the federal and state level and to
change healthcare financing and reimbursement systems. These programs may contain proposals to
increase governmental involvement in healthcare, lower reimbursement rates or otherwise change the
environment in which healthcare industry participants operate. Healthcare industry participants
may respond by reducing their investments or postponing investment decisions, including investments
in the Companys software solutions and services.
Many healthcare providers are consolidating to create integrated healthcare delivery systems with
greater market power. These providers may try to use their market power to negotiate price
reductions for the Companys software solutions and services. As the healthcare industry
consolidates, the Companys client base could be eroded, competition for clients could become more
intense and the importance of acquiring each client becomes greater.
Significant Competition
The market for healthcare information systems is intensely
competitive, rapidly evolving and subject to rapid technological change. The Company believes that
the principal competitive factors in this market include the breadth and quality of system and
software solution offerings, the stability of the information systems provider, the features and
capabilities of the information systems, the ongoing support for the system and the potential for
enhancements and future compatible software solutions.
Certain of the Companys competitors have greater financial, technical, product development,
marketing and other resources than the Company and some of its competitors offer software solutions
that it does not offer. The Companys principal existing competitors include; Eclipsys
Corporation, Epic Systems Corporation, GE Medical Systems, IDX Systems Corporation, iSoft
Corporation, McKesson Corporation, Medical Information Technology, Inc. (Meditech), Misys
Healthcare Systems and Siemens Medical Solutions Health Services Corporation, each of which offers
a suite of software solutions that compete with many of the Companys software solutions and
services. There are other competitors that offer a more limited number of competing software
solutions.
In addition, the Company expects that major software information systems companies, large
information technology consulting service providers and system integrators, Internet-based start-up
companies and others specializing in the healthcare industry may offer competitive
software/solutions or services. The pace of change in the healthcare information systems market is
rapid and there are frequent new software solution introductions, software solution enhancements
and evolving industry standards and requirements. As a result, the Companys success will depend
upon its ability to keep pace with technological change and to introduce, on a timely and
cost-effective basis, new and enhanced software solutions and services that satisfy changing client
requirements and achieve market acceptance.
Proprietary Technology May Be Subjected to Infringement Claims or May Be Infringed Upon
-The Company relies upon a combination of license agreements, confidentiality procedures, employee
nondisclosure agreements and technical measures to maintain the confidentiality and trade secrecy
of its proprietary information. The Company also relies on trademark and copyright laws to protect
its intellectual property. The Company has initiated a patent program but currently has a limited
patent
33
portfolio. As a result, the Company may not be able to protect against misappropriation of its
intellectual property.
In addition, the Company could be subject to intellectual property infringement claims as the
number of competitors grows and the functionality of its software solutions and services expands.
These claims, even if not meritorious, could be expensive to defend. If the Company becomes liable
to third parties for infringing their intellectual property rights, it could be required to pay a
substantial damage award and to develop noninfringing technology, obtain a license or cease selling
the software solutions that contain the infringing intellectual property.
Government Regulation
The healthcare industry is highly regulated at the local, state and
federal level. Consequently, the Company may be subject to such regulations, which include
regulation in the areas of healthcare fraud, medical devices and the security and privacy of
patient data, and the risk of changes in the various local, state and federal laws.
Healthcare Fraud.
The federal government continues to strengthen its position and scrutiny over
practices involving healthcare fraud affecting healthcare providers whose services are reimbursed
by Medicare, Medicaid and other government healthcare programs. Healthcare providers who are
clients of the Company are subject to laws and regulations on fraud and abuse which, among other
things, prohibit the direct or indirect payment or receipt of any remuneration for patient
referrals, or arranging for or recommending referrals or other business paid for in whole or in
part by these federal or state healthcare programs. Legislative provisions relating to healthcare
fraud and abuse give federal enforcement personnel substantial funding, powers and remedies to
pursue suspected fraud and abuse. The effect of this government regulation of the Companys clients
is difficult to predict. While the Company believes that it is in substantial compliance with any
applicable laws, many of the regulations applicable to the Companys clients and that may be
applicable to the Company, are vague or indefinite and have not been interpreted by the courts.
They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner
that could require the Companys clients to make changes in their operations or the way that they
deal with the Company. If the such laws and regulations are determined to be applicable to the
Company and if the Company fails to comply with any applicable laws and regulations, it could be
subject to sanctions or liability, including exclusion from government health programs and could
have a material adverse effect on the Companys business, results of operations or financial
condition.
Regulation of Medical Devices.
The United States Food and Drug Administration (the FDA) has
declared that certain of the Companys software solutions are medical devices that are actively
regulated under the Federal Food, Drug and Cosmetic Act (Act) and amendments to the Act. As a
consequence, the Company is subject to extensive regulation by the FDA with regard to those
software solutions that are actively regulated. If other of the Companys software solutions are
deemed to be actively regulated medical devices by the FDA, the Company could be subject to
extensive requirements governing pre- and post-marketing requirements including pre-market
notification clearance prior to marketing. Complying with these FDA regulations would be time
consuming and expensive. It is possible that the FDA may become more active in regulating computer
software that is used in healthcare.
There have been six FDA inspections since 1998 at various Cerner sites. Inspections conducted at
the Companys World Headquarters in 1999 and its Houston facility in 2002 each resulted in the
issuance of an FDA Form 483 that the Company responded to promptly. The FDA has taken no further
action with respect to either of the Form 483s that were issued in 1998 and 2002. The remaining
four FDA inspections, including an inspection at the Companys World Headquarters in 2004, resulted
in no issuance of a Form 483. The Company, however, remains subject to periodic FDA inspections
and there can be no assurances that the Company will not be required to undertake additional
actions to comply with the Act and any other applicable regulatory requirements. Any failure by
the Company to comply with the Act and any other applicable regulatory requirements could have a
material adverse effect on the Companys ability to continue to manufacture and distribute its
software solutions. The FDA has many enforcement tools including recalls, seizures, injunctions,
civil fines and/or criminal prosecutions. Any of the foregoing could have a material adverse
effect on the Companys business, results of operations or financial condition.
34
Security and Privacy of Patient Information .
State and federal laws regulate the
confidentiality of patient records and the circumstances under which those records may be released.
These regulations govern both the disclosure and use of confidential patient medical record
information and require the users of such information to implement specified security measures.
Regulations currently in place governing electronic health data transmissions continue to evolve
and are often unclear and difficult to apply.
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) requires national
standards for some types of electronic health information transactions and the data elements used
in those transactions, security standards to ensure the integrity and confidentiality of health
information and standards to protect the privacy of individually identifiable health information.
Covered entities under HIPAA, which include healthcare organizations such as the Companys clients,
were required to comply with the privacy standards by April 2003 and additional transaction
regulations by October 2003. Such organizations must also be in compliance with security
regulations by April 2005. As a business associate of the covered entities, the Company, in most
instances, must also ensure compliance with the HIPAA regulations.
The effect of HIPAA on the Companys business is difficult to predict, and there can be no
assurances that the Company will adequately address the business risks created by HIPAA and its
implementation, or that the Company will be able to take advantage of any resulting business
opportunities. Furthermore, the Company is unable to predict what changes to HIPAA, or the
regulations issued pursuant to HIPAA, might be made in the future or how those changes could affect
the Companys business or the costs of compliance with HIPAA. Evolving HIPAA-related laws or
regulations could restrict the ability of the Companys clients to obtain, use or disseminate
patient information. This could adversely affect demand for the Companys solutions if they are not
re-designed in a timely manner in order to meet the requirements of any new regulations that seek
to protect the privacy and security of patient data or enable the Companys clients to execute new
or modified healthcare transactions. The Company may need to expend additional capital, research
and development and other resources to modify its solutions to address these evolving data security
and privacy issues.
Product Related Liabilities
Many of the Companys software solutions provide data for use
by healthcare providers in providing care to patients. Although no such claims have been brought
against the Company to date regarding injuries related to the use of its software solutions, such
claims may be made in the future. Although the Company maintains product liability insurance
coverage in an amount that it believes is sufficient for its business, there can be no assurance
that such coverage will cover a particular claim that may be brought in the future, prove to be
adequate or that such coverage will continue to remain available on acceptable terms, if at all. A
successful claim brought against the Company, which is uninsured, or under-insured could materially
harm its business, results of operations or financial condition.
System Errors and Warranties
The Companys systems, particularly the
Cerner Millennium
versions, are very complex. As with complex systems offered by others, the Companys systems may
contain errors, especially when first introduced. Although the Company conducts extensive testing,
it has discovered software errors in its software solutions after their introduction. The
Companys systems are intended for use in collecting and displaying clinical information used in
the diagnosis and treatment of patients. Therefore, users of the Company software solutions have a
greater sensitivity to system errors than the market for software products generally. The
Companys agreements with its clients typically provide warranties against material errors and
other matters. Failure of a clients system to meet these criteria could constitute a material
breach under such contracts allowing the client to cancel the contract and obtain a refund and/or
damages, or could require the Company to incur additional expense in order to make the system meet
these criteria. The Companys contracts with its clients generally limit the Companys liability
arising from such claims but such limits may not be enforceable in certain jurisdictions or
circumstances. A successful claim brought against the Company, which is uninsured, or
under-insured could materially harm its business, results of operations or financial condition.
Risks Associated with the Companys Global Operations
The Company markets, sells and
services its software solutions globally. The Company has established offices around the world,
including in the Americas, Europe, in the Middle East and in the Asia Pacific region. The Company
will continue to
35
expand its global operations and enter new global markets. This expansion will require significant
management attention and financial resources to develop successful direct and indirect global sales
and support channels. The business transacted is in the local functional currency and the Company
does not currently have any material exposure to foreign currency transaction gains or losses. All
other business transactions are in U.S. dollars. To date, the Company has not entered into any
derivative financial instruments to manage foreign currency risk. In some countries, the Companys
success will depend in part on its ability to form relationships with local partners. There is a
risk that the Company may sometimes choose the wrong partner. For these reasons, the Company may
not be able to maintain or increase global market demand for its software solutions.
Global operations are subject to inherent risks, and the Companys future results could be
adversely affected by a variety of uncontrollable and changing factors. These include:
Recruitment and Retention of Key Personnel
To remain competitive in the healthcare
information technology industry, the Company must attract, motivate and retain highly skilled
managerial, sales, marketing, consulting and technical personnel, including executives,
consultants, programmers and systems architects skilled in the healthcare information technology
industry and the technical environments in which the Companys solutions operate. Competition for
such personnel in this industry is intense. The Companys failure to attract additional qualified
personnel could have a material adverse effect on the Companys prospects for long-term growth.
The success of the Company is dependent to a significant degree on the continued contributions of
key management, sales, marketing, consulting and technical personnel. The Company has succession
plans in place; however, the unexpected loss of key personnel could have a material adverse impact
to the Companys business and results of operations, and could potentially inhibit solution
development and market share advances.
Third Party Suppliers
The Company licenses or purchases intellectual property and
technology (such as software, hardware and content) from third parties, including some competitors,
and incorporates it into or sells it in conjunction with the Companys software solutions and
services, some of which intellectual property or technology is critical to the operation of the
Companys solutions. If any of the third party suppliers were to change product offerings,
increase prices or terminate the Companys licenses or supply contracts, the Company might need to
seek alternative suppliers and incur additional internal or external development costs to ensure
continued performance of the Companys solutions. Such alternatives may not be available on
attractive terms, or may not be as widely accepted or as effective as the intellectual property or
technology provided by the Companys existing suppliers. If the cost of licensing, purchasing or
maintaining these third party intellectual property or technology solutions significantly
increases, the Companys gross margin levels could significantly decrease. In addition,
interruption in functionality of the Companys solutions could adversely affect future sales of
licenses and services.
Sales Forecasts
The Companys sales forecasts may vary from actual sales in a particular
quarter. The Company uses a pipeline system, a common industry practice, to forecast sales and
trends in its business. The Companys sales associates monitor the status of all sales
opportunities, such as the date
36
when they estimate that a client will make a purchase decision and the potential dollar amount of
the sale. These estimates are aggregated periodically to generate a sales pipeline. The Company
compares this pipeline at various points in time to evaluate trends in its business. This analysis
provides guidance in business planning and forecasting, but these pipeline estimates are by their
nature speculative. The Companys pipeline estimates are not necessarily reliable predictors of
revenues in a particular quarter or over a longer period of time, partially because of changes in
the pipeline and in conversion rates of the pipeline into contracts that can be very difficult to
estimate. A variation in the expected conversion rate or timing of the pipeline into contracts, or
in the pipeline itself, could cause the Companys plan or forecast to be inaccurate and thereby
adversely affect business results. For example, a slowdown in information technology spending, or
economic conditions or a variety of other reasons can cause purchasing decisions to be delayed,
reduced in amount or cancelled, which would reduce the overall pipeline conversion rate in a
particular period of time. Because a substantial portion of the Companys contracts are completed
in the latter part of a quarter, the Company may not be able to adjust its cost structure promptly
in response to a revenue shortfall resulting from a decrease in its pipeline conversion rate in any
given fiscal quarter(s).
The Company does not have any significant market risk.
The Financial Statements and Notes required by this Item are submitted as a separate part of this
report.
None.
37
Managements Report on Internal Control over Financial Reporting
The Companys management is responsible for establishing and maintaining adequate internal control
over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934,
as amended). The Companys management assessed the effectiveness of the Companys internal control
over financial reporting as of January 1, 2005. In making this assessment, the Companys
management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO) in its Internal Control-Integrated Framework. The Companys management has
concluded that, as of January 1, 2005, the Companys internal control over financial reporting is
effective based on these criteria. The Companys independent registered public accounting firm
that audited the consolidated financial statements included in the annual report has issued an
audit report on the Companys assessment of its internal control over financial reporting, which is
included herein.
PART III
The Registrants Proxy Statement to be used in connection with the Annual Meeting of Shareholders
to be held on May 27, 2005, will contain under the caption Election of Directors certain
information required by Item 10 of Form 10-K and such information is incorporated herein by this
reference. The information required by Item 10 of Form 10-K as to executive officers is set forth
in Item 4A of Part I hereof.
The Registrants Proxy Statement to be used in connection with the Annual Meeting of Shareholders
to be held on May 27, 2005, will contain under the caption Compliance with Section 16(a) of the
Securities Exchange Act of 1934 certain information required by Item 10 of Form 10-K and such
information is incorporated herein by this reference.
Audit Committee Financial Expert
Code of Conduct; Corporate Governance Guidelines and Committee Charters
The Board of Directors of the Company has also adopted Corporate Governance Guidelines, which are
posted on the Companys website at
www.cerner.com
under About Cerner/Investors/Corporate
Governance.
The charters for the Audit Committee, the Compensation Committee and the Nominating, Governance &
Public Policy Committee are also available on the Companys
website at
www.cerner.com
under About
Cerner/Investors/Corporate Governance.
A printed copy of the Code of Conduct and the Corporate Governance Guidelines is also available to
the public at no charge by writing to Cerner Corporation, Attn. Human Resources, 2800 Rockcreek
Parkway, North Kansas City, Missouri, 64117, or calling the Companys headquarters at (816)
221-1024.
The Registrants Proxy Statement to be used in connection with the Annual Meeting of Shareholders
to be held on May 27, 2005, will contain under the caption Executive Compensation the information
required by Item 11 of Form 10-K and such information is incorporated herein by this reference.
38
The Registrants Proxy Statement to be used in connection with the Annual Meeting of Shareholders
to be held on May 27, 2005, will contain under the caption Voting Securities and Principal Holders
Thereof the information required by Item 12 of Form 10-K and such information is incorporated
herein by this reference.
The Registrants Proxy Statement to be used in connection with the Annual Meeting of Shareholders
to be held on May 27, 2005, will contain under the caption Certain Transactions the information
required by Item 13 of Form 10-K and such information is incorporated herein by this reference.
The Registrants Proxy Statement to be used in connection with the Annual Meeting of Shareholders
to be held on May 27, 2005, will contain under the caption Audit and Non-Audit Fees the
information required by Item 14 of Form 10-K and such information is incorporated herein by this
reference.
39
PART IV
40
41
42
43
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the registrant and in the capacities and on the dates
indicated:
44
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
We have audited managements assessment, included in the accompanying Managements Report on
Internal Control over Financial Reporting
,
that Cerner Corporation (the Corporation) maintained
effective internal control over financial reporting as of January 1, 2005, based on criteria
established in
Internal ControlIntegrated Framework
issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO). The Corporations management is responsible for
maintaining effective internal control over financial reporting and for its assessment of the
effectiveness of internal control over financial reporting. Our responsibility is to express an
opinion on managements assessment and an opinion on the effectiveness of the Corporations
internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control over financial reporting was
maintained in all material respects. Our audit included obtaining an understanding of internal
control over financial reporting, evaluating managements assessment, testing and evaluating the
design and operating effectiveness of internal control, and performing such other procedures as we
considered necessary in the circumstances. We believe that our audit provides a reasonable basis
for our opinion.
A companys internal control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A
companys internal control over financial reporting includes those policies and procedures that (1)
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of the company; (2) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of management and directors of the company;
and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the companys assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or
detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
In our opinion, managements assessment that Cerner Corporation maintained effective internal
control over financial reporting as of January 1, 2005, is fairly stated, in all material respects,
based on criteria established in
Internal ControlIntegrated Framework
issued by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO). Also, in our opinion, Cerner
Corporation maintained, in all material respects, effective internal control over financial
reporting as of January 1, 2005, based on criteria established in
Internal ControlIntegrated
Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
We also have audited, in accordance with the standards of the Public Company Accounting Oversight
Board (United States), the consolidated balance sheets of Cerner Corporation and subsidiaries as of
January 1, 2005 and January 3, 2004, and the related consolidated statements of operations, changes
in equity, and cash flows for each of the years in the three-year period ended January 1, 2005, and
our report dated March 11, 2005 expressed an unqualified opinion on those consolidated financial
statements.
(signed) KPMG LLP
Kansas City, Missouri
45
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders
We have audited the accompanying consolidated balance sheets of Cerner Corporation and subsidiaries
(the Corporation) as of January 1, 2005 and January 3, 2004, and the related consolidated
statements of operations, changes in equity, and cash flows for each of the years in the three-year
period ended January 1, 2005. These consolidated financial statements are the responsibility of the
Corporations management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all
material respects, the financial position of Cerner Corporation and subsidiaries as of January 1,
2005 and January 3, 2004, and the results of their operations and their cash flows for each of the
years in the three-year period ended January 1, 2005, in conformity with U.S. generally accepted
accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight
Board (United States), the effectiveness of Cerner Corporations internal control over financial
reporting as of January 1, 2005, based on criteria established in
Internal ControlIntegrated
Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO),
and our report dated March 11, 2005 expressed an unqualified opinion on managements assessment of,
and the effective operation of, internal control over financial reporting.
(signed) KPMG LLP
Kansas City, Missouri
Managements Report
The management of Cerner Corporation is responsible for the consolidated financial statements and
all other information presented in this report. The financial statements have been prepared in
conformity with U.S. generally accepted accounting principles appropriate to the circumstances,
and, therefore, included in the financial statements are certain amounts based on managements
informed estimates and judgments. Other financial information in this report is consistent with
that in the consolidated financial statements. The consolidated financial statements have been
audited by Cerner Corporations independent certified public accountants and have been reviewed by
the audit committee of the Board of Directors.
46
Consolidated Balance Sheets
See notes to consolidated financial statements.
47
Consolidated Statements of
Operations
See notes to consolidated financial statements.
48
Consolidated Statements of Changes In Equity
See notes to consolidated financial statements.
49
Consolidation Statements of Cash Flows
See notes to consolidated financial statements.
50
N
otes to Consolidated Financial Statements
1 Summary of Significant Accounting Policies
(a)
Principles of Consolidation
- The consolidated financial statements include the accounts of
Cerner Corporation and its wholly-owned subsidiaries (the Company). All significant intercompany
transactions and balances have been eliminated in consolidation.
(b)
Nature of Operations
- The Company designs, develops, markets, installs, hosts and supports
software information technology and content solutions for healthcare organizations and consumers.
The Company also implements these solutions as individual, combined or enterprise-wide systems.
(c)
Revenue Recognition
- Revenues are derived primarily from the sale of clinical, financial and
administrative information systems and solutions. The components of the system sales revenues are
the licensing of computer software, installation, subscription content and the sale of computer
hardware and sublicensed software. The components of support, maintenance and service revenues are
software support and hardware maintenance, remote hosting and outsourcing, training, consulting and
implementation services.
The Company recognizes revenue in accordance with the provisions of Statement of Position (SOP)
97-2, Software Revenue Recognition, as amended by SOP 98-4, SOP 98-9 and clarified by Staff
Accounting Bulletins (SAB) 101 Revenue Recognition in Financial Statements and SAB No. 104
Revenue Recognition and Emerging Issues Task Force Issue No. 00-21 Accounting for Revenue
Arrangements with Multiple Deliverables (EITF 00-21). SOP 97-2, as amended, generally requires
revenue earned on software arrangements involving multiple-elements to be allocated to each element
based on the relative fair values of those elements. Revenue from multiple-element software
arrangements is recognized using the residual method. Under the residual method, revenue is
recognized in a multiple-element arrangement when Company-specific objective evidence of fair value
exists for all of the undelivered elements in the arrangement (i.e. professional services, software
support, hardware maintenance, hardware and sublicensed software), but does not exist for one or
more of the delivered elements in the arrangement (i.e. software solutions). The Company allocates
revenue to each element in a multiple-element arrangement based on the elements respective fair
value, with the fair value determined by the price charged when that element is sold separately.
Specifically, the Company determines the fair value of the software support and maintenance portion
of the arrangement based on the renewal price of the software support and maintenance charged to
clients; professional services portion of the arrangement, other than installation services, based
on hourly rates which the Company charges for these services when sold apart from a software
license; and, the hardware and sublicensed software, based on the prices for these elements when
they are sold separately from the software. If evidence of the fair value cannot be established
for the undelivered elements of a license agreement, the entire amount of revenue under the
arrangement is deferred until these elements have been delivered or objective evidence can be
established.
Inherent in the revenue recognition process are significant management estimates and judgments,
which influence the timing and the amount of revenue recognition. The Company provides several
models for the procurement of its clinical, financial and administrative information systems. The
predominant method is a perpetual software license agreement, project-related installation
services, implementation and consulting services, computer hardware and sublicensed software and
software support. For those arrangements involving the use of services, the Company uses the
percentage of completion method of accounting, following the guidance in the AICPA Statement of
Position 81-1 (SOP 81-1),
Accounting for Performance of Construction-Type and Certain
Production-Type Contracts,
as prescribed by 97-2.
The Company provides installation services, which include project-scoping services, conducting
pre-installation audits and creating initial environments. Because installation services are
deemed to be essential to the functionality of the software, software license and installation
51
N
otes to Consolidated Financial Statements
services fees are recognized over the software installation period using output measures which
reflect direct labor hours incurred, beginning at software delivery and culminating at completion
of installation, typically a three-to-nine month process.
The Company also provides implementation and consulting services, which include consulting
activities that fall outside of the scope of the standard installation services. These services
vary depending on the scope and complexity requested by the client. Examples of such services may
include additional database consulting, system configuration, project management, testing
assistance, network consulting, post conversion review and application management services.
Implementation and consulting services generally are not deemed to be essential to the
functionality of the software, and thus do not impact the timing of the software license
recognition, unless software license fees are tied to implementation milestones. In those
instances, the portion of the software license fee tied to implementation milestones is deferred
until the related milestone is accomplished and related fees become billable and non-forfeitable.
Implementation fees are recognized over the service period, which may extend from nine months to
three years for multi-phased projects.
Managed services are marketed under long-term arrangements generally over periods of five to 10
years. These services typically include a perpetual license for software that the client has
elected the Company to host in its data center. Vendor-specific objective evidence for hosting and
outsourcing services are established through renewal rates in the arrangements. The Company
accounts for revenues from these arrangements as the services are performed in accordance with EITF
Issue No. 00-3, Application of AICPA Statement of Position 97-2 to Arrangements That Include the
Right to Use Software Stored on Another Entitys Hardware.
The Company also offers its solutions on an application service provider (ASP) or a term license
basis, making available Company software functionality on a remote processing basis from the
Companys data centers. The data centers provide system and administrative support as well as
processing services. Revenue on software and services provided on an ASP or term license basis is
recognized on a monthly basis over the term of the contract. The Company capitalizes related
direct costs consisting of third-party costs and direct software installation and implementation
costs. These costs are amortized over the term of the arrangement.
Software support fees are marketed under annual and multi-year arrangements and are recognized as
revenue ratably over the contracted support term. Hardware maintenance revenues are billed and
recognized monthly over the contracted maintenance term.
Subscription and content fees are generally marketed under annual and multi-year agreements and are
recognized ratably over the contracted terms.
Hardware and sublicensed software sales are generally recognized when title passes to the client.
Where the Company has contractually agreed to develop new or customized software code for a client
as a single element arrangement, the Company utilizes percentage of completion accounting in
accordance with SOP 81-1. If a contract includes multiple elements, including one or more
undelivered element, or if the agreement includes contingent revenue (as defined in EITF 00-21),
the Company complies with the provisions of EITF 00-21 and delays revenue recognition until
undelivered elements are delivered and revenue contingencies expire. When revenue is deferred all
direct and incremental costs associated with the arrangement are capitalized and amortized over the
contractual term once revenue recognition commences.
Deferred revenue is comprised of deferrals for license fees, support, maintenance and other
services for which payment has been received and for which the service has not yet been performed.
Long-term deferred revenue at January 1, 2005, represents amounts received from
52
N
otes to Consolidated Financial Statements
license fees, maintenance and other services to be earned or provided beginning in periods on or
after January 1, 2006.
The Company incurs out-of-pocket expenses in connection with its client service activities,
primarily travel, which are reimbursed by its clients. The amounts of out-of-pocket expenses and
equal amounts of related reimbursements were $32,081,000, $30,443,000 and $28,410,000 for the years
ended January 1, 2005, January 3, 2004 and December 28, 2002, respectively.
The Companys arrangements with clients typically include a deposit due upon contract signing and
date-based licensed software payment terms and payments based upon delivery for services, hardware
and sublicensed software. The Company has periodically provided long-term financing options to
creditworthy clients through third party financing institutions and has on occasion directly
provided extended payment terms from contract date. Certain of these receivables have been
assigned on a non-recourse basis to third party financing institutions. The Company accounts for
the assignment of these receivables as true sales as defined in FASB Statement No. 140,
Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities.
Provided all other revenue recognition criteria have been met, the Company recognizes revenue for
these arrangements under its normal revenue recognition criteria, net of any payment discounts from
financing transactions.
The terms of the Companys software license agreements with its clients generally provide for a
limited indemnification of such intellectual property against losses, expenses and liabilities
arising from third-party claims based on alleged infringement by the Companys solutions of an
intellectual property right of such third party. The terms of such indemnification often limit the
scope of and remedies for such indemnification obligations and generally include a right to replace
or modify an infringing solution. To date, the Company has not had to reimburse any of its clients
for any losses related to these indemnification provisions pertaining to third-party intellectual
property infringement claims. For several reasons, including the lack of prior indemnification
claims and the lack of a monetary liability limit for certain infringement cases under the terms of
the corresponding agreements with its clients, the Company cannot determine the maximum amount of
potential future payments, if any, related to such indemnification provisions.
(d)
Fiscal Year
- The Companys fiscal year ends on the Saturday closest to December 31. Fiscal
year 2003 consisted of 53 weeks and fiscal years 2004 and 2002 consisted of 52 weeks each. All
references to years in these notes to consolidated financial statements represent fiscal years
unless otherwise noted.
(e)
Software Development Costs
- Costs incurred internally in creating computer software products
are expensed until technological feasibility has been established upon completion of a detailed
program design. Thereafter, all software development costs are capitalized and subsequently
reported at the lower of amortized cost or net realizable value. Capitalized costs are amortized
based on current and expected future revenue for each product with minimum annual amortization
equal to the straight-line amortization over the estimated economic life of the product. The
Company is amortizing capitalized costs over five years. During 2004, 2003 and 2002, the Company
capitalized $58,912,000, $58,736,000 and $49,984,000, respectively, of total software development
costs of $188,264,000, $179,999,000 and $149,985,000, respectively. Amortization expense of
capitalized software development costs in 2004, 2003 and 2002, was $42,237,000, $34,973,000 and
$29,619,000, respectively, and accumulated amortization was $207,382,000, $165,145,000 and
$130,172,000, respectively.
(f)
Cash Equivalents
Cash equivalents consist of short-term marketable securities with
original maturities less than ninety days.
(g)
Inventory
- Inventory consists primarily of computer hardware and sub-licensed software held
for resale and is recorded at the lower of cost (first-in, first-out) or market.
53
N
otes to Consolidated Financial Statements
(h)
Property and Equipment
- Property, equipment and leasehold improvements are stated at cost.
Depreciation of property and equipment is computed using the straight-line method over periods of 3
to 50 years. Amortization of leasehold improvements is computed using a straight-line method over
the lease terms, which range from periods of two to fifteen years.
(i)
Earnings per Common Share
Basic earnings per share (EPS) excludes dilution and is computed
by dividing income available to common stockholders by the weighted-average number of common shares
outstanding for the period. Diluted EPS reflects the potential dilution that could occur if
securities or other contracts to issue stock were exercised or converted into common stock or
resulted in the issuance of common stock that then shared in the earnings of the Company. A
reconciliation of the numerators and the denominators of the basic and diluted per-share
computations is as follows:
(In thousands, except per share data)
Options to purchase 1,569,000, 3,054,000 and 2,390,000 shares of common stock at per share
prices ranging from $45.00 to $273.72, $32.50 to $574.82 and $43.13 to $574.82, were outstanding at
the end of 2004, 2003 and 2002, respectively, but were not included in the computation of diluted
earnings per share because the options exercise price was greater than the average market price of
the common shares for the period.
(j)
Foreign Currency
- Assets and liabilities of foreign subsidiaries whose functional currency is
the local currency are translated into U.S. dollars at exchange rates prevailing at the balance
sheet date. Revenues and expenses are translated at average exchange rates for the year. The net
exchange differences resulting from these translations are reported in accumulated other
comprehensive income. Gains and losses resulting from foreign currency transactions are included
in the consolidated statements of operations. The net gain (loss) resulting from foreign currency
transactions was ($479,000), $1,376,000 and $1,955,000 in 2004, 2003 and 2002, respectively.
54
N
otes to Consolidated Financial Statements
(k)
Income Taxes
- Deferred tax assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled.
(l)
Goodwill and Other Intangible Assets
The Company accounts for goodwill under the
provisions of Statement of Financial Accounting Standards (SFAS) No. 142, Goodwill and Other
Intangible Assets. As a result, goodwill and intangible assets with indefinite lives are no
longer amortized but are evaluated for impairment annually or whenever there is an impairment
indicator. All goodwill is assigned to a reporting unit, where it is subject to an impairment test
based on fair value. The Company assesses its goodwill for impairment in the second quarter of its
fiscal year. There was no impairment of goodwill in 2004 and 2003. The Company used a discounted
cash flow analysis to determine the fair value of the reporting units for all periods tested. The
Companys intangible assets, other than goodwill or intangible assets with indefinite lives, are
all subject to amortization and are summarized as follows:
(In thousands)
Amortization expense was $6,679,000, $6,592,000 and $4,482,000 for the years ended 2004, 2003
and 2002, respectively.
Estimated aggregate amortization expense for each of the next five years is as follows:
The changes in the carrying
amount of goodwill for the 12 months ended January 1, 2005 are
as follows:
(m)
Use of Estimates
- The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of America requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ
from those estimates.
55
(n)
Concentrations
Substantially all of the Companys cash and cash equivalents and short-term
investments, are held at three major U.S. financial institutions. The majority of the Companys
cash equivalents consist of U.S. Government Federal Agency Securities, short-term marketable
securities, and overnight repurchase agreements. Deposits held with banks may exceed the amount of
insurance provided on such deposits. Generally these deposits may be redeemed upon demand and,
therefore, bear minimal risk.
Substantially all of the Companys clients are integrated delivery networks, hospitals, and other
healthcare related organizations. If significant adverse macro-economic factors were to impact
these organizations it could materially adversely affect the Company. The Companys access to
certain software and hardware components is dependent upon single and sole source suppliers. The
inability of any supplier to fulfill supply requirements of the Company could affect future
results.
The Company performs ongoing credit evaluations of its clients and generally does not require
collateral from its clients. The Company maintains an allowance for potential losses based on
specific identification, historical experience and managements judgments. The Companys allowance
for doubtful accounts as of January 1, 2005 and January 3, 2004 was $17,583,000 and $12,056,000,
respectively.
(o)
Accounting for Stock Options
The Company applies the intrinsic-value-based method of
accounting prescribed by Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock
Issued to Employees, and related interpretations including FASB Interpretation No. 44, Accounting
for Certain Transactions involving Stock Compensation, an interpretation of APB Opinion No. 25,
issued in March 2000, to account for its fixedplan stock options. Under this method for fixed
awards, compensation expense is recorded on the date of grant only if the current market price of
the underlying stock exceeded the exercise price. Statement of Financial Accounting Standards No.
123, Accounting for Stock-Based Compensation, established accounting and disclosure requirements
using a fair-value-based method of accounting for stock-based employee compensation plans. As
allowed by SFAS No. 123, the Company has elected to continue to apply the intrinsic-value-based
method of accounting described above, and has adopted only the disclosure requirements of SFAS No.
123. The following is a reconciliation of reported net earnings to adjusted net earnings had the
Company recorded compensation expense based on the fair value at the grant date for its stock
options under SFAS 123 for the years ended 2004, 2003 and 2002.
(In thousands, except per share data)
56
N
otes to Consolidated Financial Statements
Pro forma net earnings reflect only options granted since January 1, 1995. Therefore, the
full impact of calculating compensation expense for stock options under FAS 123 is not reflected in
the pro forma net earnings amounts presented above, because compensation cost is reflected over the
options vesting period of 10 years for these options. Compensation expense for options granted
prior to January 1, 1995 is not considered.
(p)
Reclassifications
Certain prior year amounts have been reclassified to conform to the
current year consolidated financial statement presentation.
(q)
Accounting for Variable Interest Entities
- On September 27, 2003, the Company adopted
Financial Accounting Standards Board Interpretation No. 46 (FIN 46) as amended by FIN 46R,
Consolidation of Variable Interest Entities an Interpretation of APB No. 51. The Interpretation
provides guidance on the identification of entities for which control is achieved through means
other than through voting rights (variable interest entities or VIEs) and how to determine
when and which business enterprises should consolidate the VIE (the primary beneficiary).
2 Business Acquisitions and Divestiture
During the three years ended January 1, 2005, the Company completed five acquisitions, which were
accounted for under the purchase method of accounting. Pro forma results of operations have not
been presented and will not be presented for any of the acquisitions because the effects of these acquisitions were not
material to the Company on either an individual or an aggregate basis. The results of operations of
each acquisition are included in the Companys consolidated statement of operations from the date
of each acquisition.
On March 15, 2004 the Company sold the referential content portion of Zynx Health Incorporated
(Zynx) for $12 million. The Company retained the life sciences portion of the business, which is
engaged in selling life sciences data to pharmaceutical companies for use in research, and the
Company retained the rights to use the Zynx content in its solutions going forward. The sale of
Zynx resulted in a gain of $1,826,000, net of $1,197,000 of tax, and has been included in Other
Income, net in the accompanying consolidated statements of operations.
A summary of the Companys purchase acquisitions for the three years ended January 1, 2005, is
included in the following table (in millions, except share amounts):
57
N
otes to Consolidated Financial Statements
Amounts allocated to intangibles are amortized on a straight-line basis over five to seven
years. Amounts allocated to software are amortized based on current and expected future revenues
for each product with minimum annual amortization equal to the straight-line amortization over the
estimated economic life of the product.
(b) In March 2004 the Company amended the April 2002 purchase agreement with Cedars-Sinai
Medical Center (Cedars). The amendment requires the Company to pay at least $7.5 million in cash
to Cedars related to the original purchase of Zynx, which resulted in $7.5 million of additional
goodwill, along with up to $1 million in software discounts if Cedars chooses to license solutions
from the Company. At January 1, 2005 the Company had made payments of $2.5 million to Cedars. The
balance of the $7.5 million note will be payable on April 30, 2007.
On January 3, 2005, the Company completed the purchase of assets of the medical business
division of VitalWorks, Inc. for $100 million, which was funded with existing cash of approximately
$65 million and borrowings on the revolving line of credit of approximately $35 million. The
medical business consists of delivering and supporting physician practice management, electronic
medical record, electronic data interchange and emergency department information solutions and
related products and services to physician practices, hospital emergency
58
N
otes to Consolidated Financial Statements
departments, management service organizations and other related entities. The Company is in the
process of determining its allocation of the purchase price to the net assets acquired. A Form
8-K, disclosing the completion of the acquisition of assets was filed with the Securities and
Exchange Commission on January 7, 2005, and an amended 8-K
reflecting pro forma financials will not be filed as explained above.
3 Receivables
Receivables consist of accounts receivable and contracts receivable. Accounts receivable represent
recorded revenues that have been billed. Contracts receivable represent recorded revenues that are
billable by the Company at future dates under the terms of a contract with a client. Billings and
other consideration received on contracts in excess of related revenues recognized are recorded as
deferred revenue. A summary of receivables is as follows:
Substantially all receivables are derived from sales and related support and maintenance of
the Companys clinical, administrative and financial information systems and solutions to
healthcare providers located throughout the United States and in certain foreign countries.
Included in receivables at the end of 2004 and 2003 are amounts due from healthcare providers
located in foreign countries of $33,304,000 and $29,072,000 respectively. Consolidated revenues
include foreign sales of $64,333,000, $54,191,000 and $36,634,000 during 2004, 2003 and 2002,
respectively. Consolidated long-lived assets at the end of 2004 and 2003 include foreign
long-lived assets of $5,176,000 and $4,254,000 respectively. Revenues and long-lived assets from
any one foreign country are not material.
The Company provides an allowance for estimated uncollectible accounts based on specific
identification, historical experience and managements judgment. At the end of 2004 and 2003 the
allowance for estimated uncollectible accounts was $17,583,000 and
$12,056,000, respectively.
4 Property and Equipment
A summary of property, equipment, and leasehold improvements stated at cost, less accumulated
depreciation and amortization, is as follows:
59
N
otes to Consolidated Financial Statements
5 Indebtedness
In December 2002, the Company completed a $60,000,000 private placement of debt pursuant to a Note
Agreement. The Series A Senior Notes, with a $21,000,000 principal amount at 5.57%, are payable in
three equal installments beginning in December 2006. The Series B Senior notes, with a $39,000,000
principal amount at 6.42%, are payable in 4 equal annual installments beginning December 2009. The
proceeds were used to repay the outstanding amount under the Companys credit facility and for
general corporate purposes. The Note Agreement contains certain net worth and fixed charge
coverage covenants and provides certain restrictions on the Companys ability to borrow, incur
liens, sell assets and pay dividends. The Company was in compliance with all covenants at January
1, 2005.
In May 2002, the Company expanded its credit facility by entering into an unsecured credit
agreement with a group of banks led by US Bank. This agreement provides for a current revolving
line of credit for working capital purposes. The current revolving line of credit is unsecured and
requires monthly payments of interest only. Interest is payable at the Companys option at a rate
based on prime (5.25% at January 1, 2005) or LIBOR (2.4% at January 1, 2005) plus 2%. The interest
rate may be reduced by up to 1.15% if certain net worth ratios are maintained. The agreement
contains certain net worth, current ratio, and fixed charge coverage covenants and provides certain
restrictions on the Companys ability to borrow, incur liens, sell assets, and pay dividends. A
commitment fee of 3/10% to 1/2% is payable quarterly based on the usage of the revolving line of
credit. The revolving line of credit matures on May 31, 2007. At January 1, 2005, the Company had
no outstanding borrowings under this agreement and had $90,000,000 available for working capital
purposes. On January 10, 2005, the Company drew down $35,000,000 from its revolving line of credit
in connection with the acquisition of the medical business division of VitalWorks, Inc. (See Note
2 to the consolidated financial statements.)
In April 1999, the Company completed a $100,000,000 private placement of debt pursuant to a Note
Agreement. The Series A Senior Notes, with a $60,000,000 principal amount at 7.14%, are payable in
five equal annual installments beginning in April 2002. The Series B Senior Notes, with a
$40,000,000 principal amount at 7.66%, are payable in six equal annual installments beginning April
2004. The proceeds were used to retire the Companys existing $30,000,000 of debt, and the
remaining funds were used for capital improvements and to strengthen the Companys cash position.
The Note Agreement contains certain net worth, current ratio, and fixed charge coverage covenants
and provides certain restrictions on the Companys ability to borrow, incur liens, sell assets, and
pay dividends. The Company was in compliance with all covenants at January 1, 2005.
In March 2004, the Company issued a $7,500,000 promissory note to Cedars-Sinai Medical Center of
which $2,500,000 was repaid in October 2004. The balance of the note will be payable on April 30,
2007.
The Company also has capital lease obligations amounting to $8,378,000, payable over the next four
years.
60
N
otes to Consolidated Financial Statements
The aggregate maturities for the Companys long-term debt, including capital lease obligations, is
as follows (in thousands):
The Company estimates the fair value of its long-term, fixed-rate debt using a discounted cash
flow analysis based on the Companys current borrowing rates for debt with similar maturities. The
fair value of the Companys long-term debt was approximately $109,746,000 and $147,072,000 at
January 1, 2005 and January 3, 2004, respectively.
6 Other Income (Expense)
A summary of interest income and expense is as follows:
Included in Other Income (Expense) in 2002 were gains on sale of investments and impairments
on Investments as described below.
In the second quarter of 2002, the Company sold its remaining 14,820,527 shares of WebMD for
$90,119,000. Accordingly, the Company recorded an investment gain of $2,736,000, net of $1,572,000
in tax, as a result of the sale. Since the shares sold had a lower income tax basis, the sale
resulted in the transfer of approximately $29,638,000 of deferred tax liabilities to income taxes
payable in the second quarter of 2002. In the third quarter of 2002, the Company made a cash
payment of tax in the amount of $31,200,000 related to the investment gain.
In December 2002, the Company exercised 1,048,783 warrants of WebMD with an exercise price of $3.08
and a cost basis and carrying value of $4,146,000. The warrants were scheduled to expire on
January 26, 2003. In December 2002, the Company sold 1,048,783 shares of WebMD for $8,242,000.
Accordingly, the Company recorded an investment gain of $527,000, net of $342,000 in tax, as a
result of the exercise of the warrants and the sale of the shares.
The Company had certain other minority equity investments in non-publicly traded securities. These
investments were generally carried at cost as the Company owned less than 20% of the voting equity
and did not have the ability to exercise significant influence over these companies. Based on
events occurring in the fourth quarter of 2002, the Company recorded a charge of $6,281,000, net of
tax of $3,623,000, for the impairment of various investments of non-publicly traded securities.
The charge is primarily related to a $3,464,000, net of tax, write down of the Companys investment
in Protocare, Inc., a non-publicly traded company.
7 Stock Options, Warrants and Equity
At the end of 2004 and 2003, the Company had 1,000,000 shares of authorized but unissued preferred
stock, $.01 par value.
61
N
otes to Consolidated Financial Statements
At January 1, 2005, the Company had four fixed stock option plans. Initially, under Stock Option
Plan D, the Company was authorized to grant to associates, directors, consultants or advisors to
the Company options to purchase up to 50,000 shares of common stock through January 1, 2005.
Additional shares which were approved by the Companys shareholders on May 17, 1994, May 16, 1995
and May 22, 1998, increasing the total authorized to grant to 4,600,000 shares. The options are
exercisable at a price (not less than fair market value on the date of grant) and during a period
determined by the Stock Option Committee. Options under this plan currently vest over periods of
up to ten years and are exercisable for periods of up to 25 years. The Company, per the terms of
the plan, is not permitted to issue any more stock options under Plan
D, after January 1, 2005.
Initially, under Stock Option Plan E, the Company was authorized to grant to associates (other than
officers subject to the provisions of Section 16(a) of the Securities and Exchange Act of 1934),
consultants, or advisors to the Company options to purchase up to 2,000,000 shares of common stock
through January 1, 2005. Additional shares of 1,100,000 and 1,000,000 were approved by the
Companys Board of Directors on December 8, 2000 and March 9, 2001, respectively, increasing the
total authorized to grant to 4,100,000 shares. The options are exercisable at a price (not less
than fair market value on the date of grant) and during a period determined by the Stock Option
Committee. Options under this plan currently vest over periods of up to ten years and are
exercisable for periods of up to 25 years. The Company, per the terms of the plan, is not
permitted to issue any more stock options under Plan E, after January 1, 2005.
Under the 2001 Long-Term Incentive Plan F, the Company is authorized to grant to associates,
directors and consultants 2,000,000 shares of common stock awards. Awards under this plan may
consist of stock options, restricted stock and performance shares, as well as other awards such as
stock appreciation rights, phantom stock and performance unit awards which may be payable in the
form of common stock or cash. However, not more than 500,000 of such shares will be available to
granting any types of grants other than options or stock appreciation rights. The company granted
7,500 shares of restricted stock from Plan F to members of the Board of Directors on July 6, 2004.
These grants were valued at $42.31 (the fair market value on the date of grant) and vest on May 26,
2005 provided the recipient has continuously served on the Board of Directors through such date.
The expense associated with these grants is being recognized over the period from the date of grant
to the vest date. The Company recognized expenses related to the restricted stock of $173,000 in
2004.
Long-Term Incentive Plan G was approved by the Companys shareholders on May 28, 2004. Under the
2004 Long-Term Incentive Plan G, the Company is authorized to grant to associates and directors
2,000,000 shares of common stock awards. Awards under this plan may consist of stock options,
restricted stock and performance shares, as well as other awards such as stock appreciation rights,
phantom stock and performance unit awards which may be payable in the form of common stock or cash.
The Company has also granted 854,085 other non-qualified stock options under separate agreements to
employees and certain third parties. These options are exercisable at a price equal to or greater
than the fair market value on the date of grant. These options vest over periods of up to six
years and are exercisable for periods of up to ten years. The Company recognized expenses related
to the non-qualified stock options of $34,000 and $90,000 for 2003 and 2002, respectively. No
expense related to the non-qualified stock options was recognized in 2004.
A combined summary of the status of the Companys four fixed stock option plans and other stock
options at the end of 2004, 2003 and 2002, and changes during these years ended is presented below:
62
N
otes to Consolidated Financial Statements
The following table summarizes information about fixed and other stock options outstanding at
January 1, 2005.
The per share weighted-average fair value of stock options granted during 2004, 2003 and 2002
was $25.75, $15.34 and $25.80, respectively, on the date of grant using the Black Scholes
option-pricing model with the following weighted-average assumptions:
8 Associate Stock Purchase Plan
The Company established an Associate Stock Purchase Plan (ASPP) in 2001, which qualifies under
Section 423 of the Internal Revenue Code. All full-time associates are eligible to participate.
Participants may elect to make contributions from 1% to 20% of compensation to the ASPP, subject to
annual limitations determined by the Internal Revenue Service. Participants may purchase Company
Common Stock at a 15% discount on the last day of the purchase period. Under APB No. 25 the ASPP
qualifies as a non-compensatory plan and no compensation expense has been recognized. The purchase
of the Companys common stock is made through the ASPP on the open market and subsequently reissued
to the associates.
9 Foundations Retirement Plan
The Cerner Corporation Foundations Retirement Plan (the Plan) is established under Section 401(k)
of the Internal Revenue Code. All full-time associates are eligible to participate. Participants
may elect to make pretax contributions from 1% to 80% of compensation to the Plan, subject to
annual limitations determined by the Internal Revenue Service. Participants may direct
contributions into mutual funds, a money market fund, or a Company stock fund. The Company makes
matching contributions to the Plan, on behalf of participants, in an amount equal to 33% of the
first 6% of the participants contribution. The Companys expense for the plan amounted to
$5,994,000, $5,325,000 and $4,347,000 for 2004, 2003 and 2002, respectively.
63
N
otes to Consolidated Financial Statements
The Company added a discretionary match to the Plan in 2000. Contributions are based on attainment
of established earnings per share goals for the year. Only participants in the Plan are eligible
to receive the discretionary match contribution. For the years ended 2004, 2003 and 2002 the
Company expensed $5,186,000, $0 and $5,345,000 for discretionary distributions, respectively.
10 Income Taxes
Income tax expense for the years ended 2004, 2003 and 2002, consists of the following:
Temporary differences between the financial statement carrying amounts and tax basis of assets
and liabilities that give rise to significant portions of deferred income taxes at the end of 2004
and 2003 relate to the following:
Based upon the level of historical taxable income and projections for future taxable income
over the periods which the deferred tax assets are deductible, as well as the scheduled reversal of
deferred tax liabilities, management believes it is more likely than not the Company will realize
the benefit of these deductible differences. At January 1, 2005, the Company has net operating
loss carryforwards subject to Section 382 of the Internal Revenue Code for Federal income tax
purposes of $20.9 million which are available to offset future Federal taxable income, if any,
through 2024.
64
N
otes to Consolidated Financial Statements
The effective income tax rates for 2004, 2003, and 2002 were 40%, 40%, and 39%, respectively.
These effective rates differ from the federal statutory rate of 35% as follows:
Income taxes payable are reduced by the tax benefit resulting from disqualifying dispositions
of stock acquired under the Companys stock option plans. The 2004, 2003, and 2002 benefits of
$9,191,000, $1,876,000, and $1,561,000, respectively, are treated as increases to additional
paid-in capital.
11 Related Party Transactions
The Company has made loans to the Companys senior management under the terms of the Executive
Stock Purchase Program (Program). The purpose of the Program is to advance the interests of the
Company, the Companys senior management, and the Companys shareholders by offering the Companys
senior management an incentive to purchase shares of the Companys stock on the open market.
Pursuant to the Program, the Company provided Program loans to executives to help finance up to 50%
of the total purchase price of the stock purchased. All Program loans have a term of five (5)
years, at an interest rate of 5.5%. Principal and interest is not due until the end of the
five-year loan term, unless the executive terminates employment. Executives may also elect to pay
interest annually. If interest is not paid annually, it will compound annually. All Program loans
are full recourse to senior management including the purchased shares and any pledged shares. The
balance of these loans, including accrued interest, at January 1, 2005 and January 3, 2004 was
$30,000 and $1,710,000, respectively. Loans to the Companys senior executives are no longer
permitted under this program.
The Company leases an airplane from a company owned by Mr. Neal L. Patterson and Mr. Clifford W.
Illig. The airplane is leased on a per mile basis with no minimum usage guarantee. The lease rate
is believed to approximate fair market value for this type of aircraft. During 2004 and 2003,
respectively, the Company paid an aggregate of $574,000 and $839,000 for the rental of the
airplane. The airplane is used principally by the Companys top executives to make client visits.
65
N
otes to Consolidated Financial Statements
12 Commitments
The Company leases space to unrelated parties in its North Kansas City headquarters complex under
noncancelable operating leases. Included in other revenues is rental income of $63,000, $145,000
and $87,000 in 2004, 2003 and 2002, respectively.
The Company is committed under operating leases for office space and computer equipment through May
2013. Rent expense for office and warehouse space for the Companys regional and global offices
for 2004, 2003 and 2002 was $6,470,000, $5,345,000 and $5,175,000, respectively. Aggregate minimum
future payments (in thousands) under these noncancelable operating leases are as follows:
13 Segment Reporting
Statement of Financial Accounting Standards No. 131, Disclosures about Segments of an Enterprise
and Related Information establishes annual and interim reporting standards for operating segments
of a company. It also requires entity-wide disclosures about the products and services an entity
provides, the material countries in which it holds assets and reports revenues, and its major
clients. In 2003, the Company organized geographically. The Companys six geographic business
segments are: Great Lakes, Mid-America, North Atlantic, Southeast, West and Global. The Company
has not presented comparable information for 2002 as the necessary information is not available and
the cost to develop it would be excessive.
Revenues are derived primarily from the sale of clinical, financial and administrative information
systems and solutions. The cost of revenues includes the cost of third party consulting services,
computer hardware and sublicensed software purchased from computer and software manufacturers for
delivery to clients. It also includes the cost of hardware maintenance and sublicensed software
support subcontracted to the manufacturers. Operating expenses incurred by the geographic business
segments consist of sales and client service expenses including salaries of sales and client
service personnel, communications expenses and unreimbursed travel expenses. Performance of the
segments is assessed at the operating earnings level and, therefore, the segment operations have
been presented as such. Other includes revenues not generated by the operating segments and
expenses such as software development, marketing, general and administrative and depreciation that
have not been allocated to the operating segments. The Company does not track assets by
geographical business segment.
Accounting policies for each of the reportable segments are the same as those used on a
consolidated basis. The following table presents a summary of the operating information for the
years ended January 1, 2005 and January 3, 2004.
66
N
otes to Consolidated Financial Statements
14 Accrued Vacation Pay Adjustment
In conjunction with a review of the process for calculating the liability for accrued vacation pay
at the end of the third quarter of 2004, the Company determined that the liability on the balance
sheet relating to periods prior to 2004 was understated by $3,346,000. While the Company was fully
accrued for all vested vacation that would be subject to payout upon termination, the Company
understated the liability for accumulated vacation that could be used in subsequent periods by
associates in excess of the vested amount payable upon termination.
The expense, if properly recorded in 2000 through 2003, would have increased 2003 net earnings by
$0.1 million and would have decreased net earnings by $0.4 million in 2002, $0.6 million in 2001,
and $1.2 million in 2000. The cumulative impact on net earnings is a decrease of $2.1 million for
this four-year period. The impact on 2004 net earnings is a positive $8 thousand. As the impact
to prior years annual financial statements was not material, Cerner recorded additional expense of
$3,346,000, $2,076,000 million after-tax, in the 2004 third quarter to appropriately reflect the
liability as of October 2, 2004. The Company has revised its process for calculating the liability
for accumulated vacation to accurately report this information in the future.
67
N
otes to Consolidated Financial Statements
15 Quarterly Results (unaudited)
Selected quarterly financial data for 2004 and 2003 is set forth below:
68
Schedule II
Cerner Corporation
Report of Independent Registered
The Board of Directors and Stockholders
Under date of March 11, 2005, we reported on the consolidated balance sheets of Cerner Corporation
and subsidiaries (the Company) as of January 1, 2005 and January 3, 2004, and the related
consolidated statements of operations, changes in equity, and cash flows for each of the years in
the three-year period ended January 1, 2005, which are included in the Companys 2004 annual report
on Form 10-K. In connection with our audits of the aforementioned consolidated financial
statements, we also have audited the related consolidated financial statement schedule as listed
under Item 15(a)(2). This consolidated financial statement schedule is the responsibility of the
Companys management. Our responsibility is to express an opinion on this consolidated financial
statement schedule based on our audits.
In our opinion, this consolidated financial statement schedule, when considered in relation to the
basic consolidated financial statements taken as a whole, presents fairly, in all material
respects, the information set forth therein.
Kansas City, Missouri
2004
2003
High
Low
Last
High
Low
Last
47.63
37.36
44.81
38.45
30.22
32.81
47.25
39.89
42.74
32.38
16.50
23.25
46.94
41.37
44.61
37.55
20.08
31.42
53.59
43.98
53.17
46.12
30.87
38.51
2000
2004
2003
2002
2001
(8)(9)
(In thousands, except per share data)
(1)(2)
(3)(4)(5)
(6)(7)
(10)(11)(12)
$
926,356
839,587
780,262
560,802
414,551
111,464
78,097
90,820
61,350
21,922
107,920
71,222
80,625
(63,314
)
172,123
(786
)
64,648
42,791
48,022
(42,366
)
105,265
1.79
1.21
1.36
(1.21
)
3.08
1.72
1.18
1.30
(1.21
)
2.96
36,087
35,355
35,458
34,907
34,123
37,571
36,356
37,050
34,907
35,603
$
310,229
246,412
282,135
189,488
186,181
982,265
854,252
779,279
712,302
616,411
108,804
124,570
136,636
92,132
102,299
597,485
494,680
441,244
394,839
343,717
Table of Contents
(1)
Includes a gain on the sale of Zynx Health Incorporated. The impact of this gain
is a $1.8 million increase, net of $1.2 million tax expense, in net earnings and
increase to diluted earnings per share of $.05 for 2004.
(2)
Includes a charge for vacation accrual of $3.3 million included in general and
administrative. The impact of this charge is a $2.1 million decrease, net of $1.2
million tax benefit, in net earnings and a decrease to diluted earnings per share of
$.06 for 2004.
(3)
Includes a gain on the sale of shares of WebMD common stock. The impact of
this gain is a $3.3 million, net of $1.9 million tax expense, increase in net earnings
and an increase to diluted earnings per share of $.09 for 2002.
(4)
Includes a charge for impairment of investments. The impact of this charge is
a $6.3 million, net of $3.6 million tax benefit, decrease in net earnings and a
decrease to diluted earnings per share of $.17 for 2002.
(5)
Includes the cumulative effect of a change in accounting for goodwill. The
impact of this change is a $.8 million, net of $.5 million tax benefit, decrease in net
earnings and a decrease to diluted earnings per share of $.02 for 2002.
(6)
Includes a gain on the settlement of the WebMD performance warrants. The
impact of this gain is a $4.8 million, net of $2.7 million tax expense, increase in net
earnings and an increase to diluted earnings per share of $.13 for 2001.
(7)
Includes a charge on the adjustment of the carrying value of the WebMD shares.
The impact of this charge is an $81.4 million, net of $46.1 million tax benefit,
decrease in net earnings and a decrease to diluted earnings per share of $2.21 for
2001.
(8)
Includes an investment gain of $120.4 million, net of $68.3 million tax
expense, related to the conversion of shares of CareInsite common stock to shares of
WebMD common stock. The impact of this investment gain was to increase diluted
earnings per share by $3.38 for 2000.
(9)
Includes an investment loss of $24.5 million, net of $13.9 million tax benefit,
related to the sale of shares of WebMD common stock. The impact of this investment
loss was to decrease diluted earnings per share by $.69 for 2000.
(10)
Includes a charge of $6.7 million related to the write-down of intangible
assets associated with the acquisition of Health Network Ventures, Inc. The impact of
this charge was to decrease diluted earnings per share by $.19 for 2000.
(11)
Includes a charge of $3.2 million related to the acquisition of CITATION
Computer Systems, Inc. The impact of this charge on diluted earnings per share was
($.09) for 2000.
(12)
Includes a charge of $1.0 million, net of $.7 million tax benefit, related to
the acquisition of ADAC Healthcare Information Systems, Inc. The impact of this charge
was to decrease diluted earnings per share by $.03 for 2000.
Table of Contents
Item 7.
Managements Discussion and Analysis of Financial Condition and Results of Operations
Table of Contents
Table of Contents
Table of Contents
Operating Segments
Great
Mid-
North
South-
2004
Lakes
America
Atlantic
east
West
Global
Other
Total
$
157,627
$
201,570
$
179,520
$
148,186
$
150,694
$
64,333
$
24,426
$
926,356
29,805
32,588
41,050
35,487
28,577
8,938
19,903
196,348
27,689
31,618
30,487
33,267
33,827
38,411
423,245
618,544
57,494
64,206
71,537
68,754
62,404
47,349
443,148
814,892
$
100,133
$
137,364
$
107,983
$
79,432
$
88,290
$
16,984
$
(418,722
)
$
111,464
Operating Segments
Great
Mid-
North
South-
2003
Lakes
America
Atlantic
east
West
Global
Other
Total
$
153,949
$
160,633
$
149,585
$
145,312
$
161,840
$
54,191
$
14,077
$
839,587
36,910
35,447
37,520
40,784
28,321
13,450
1,858
194,290
24,897
24,815
26,788
29,454
28,223
35,814
397,209
567,200
61,807
60,262
64,308
70,238
56,544
49,264
399,067
761,490
$
92,142
$
100,371
$
85,277
$
75,074
$
105,296
$
4,927
$
(384,990
)
$
78,097
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Payments due by period
2010 and
Contractual Obligations (in thousands)
2005
2006
2007
2008
2009
thereafter
Total
21,908
28,558
20,207
14,373
16,417
29,249
130,712
16,614
12,234
6,428
4,964
3,577
6,634
50,451
250
100
100
25
475
2,872
100
2,972
1,800
1,700
3,500
43,444
42,692
26,735
19,362
19,994
35,883
188,110
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Greater difficulty in collecting accounts receivable and longer collection periods;
Difficulties and costs of staffing and managing global operations;
The impact of economic conditions outside the United States;
Unexpected changes in regulatory requirements;
Certification or regulatory requirements;
Reduced protection of intellectual property rights in some countries;
Potentially adverse tax consequences;
Different or additional functionality requirements;
Trade protection measures and other regulatory requirements;
Service provider and government spending patterns;
Natural disasters, war or terrorist acts;
Poor selection of a partner in a country; and
Political conditions which may impact sales or threaten the safety of associates or the
continued presence of the Company in these countries.
Table of Contents
Item 7A.
Quantitative and Qualitative Disclosures about Market Risk
Item 8.
Financial Statements and Supplementary Data
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9.A.
Controls and Procedures
a)
Evaluation of disclosure controls and procedures. The Companys Chief Executive
Officer (CEO) and Chief Financial Officer (CFO) have evaluated the effectiveness of the
Companys disclosure controls and procedures (as defined in the Exchange Act Rules
13a-15(e) and 15d-15(e)) as of the end of the period covered by the Annual Report (the
Evaluation Date). They have concluded that, as of the Evaluation Date, these disclosure
controls and procedures were effective to ensure that material information relating to the
Company and its consolidated subsidiaries would be made known to them by others within
those entities and would be disclosed on a timely basis.
b)
There were no changes in the Companys internal controls over financial reporting
during the year ended January 1, 2005 that have materially affected, or are reasonably
likely to materially affect, its internal controls over financial reporting.
c)
The Companys management, including its Chief Executive Officer and Chief Financial
Officer, cannot provide complete assurance that its disclosure controls and procedures or
the Companys internal controls will prevent all error and all fraud. A control system, no
matter how well conceived and operated, can provide only reasonable, not absolute,
assurance that the objectives of the control system are met. Further, the design of a
control system must reflect the fact that there are resource constraints, and the benefits
of controls must be considered relative to their costs. Because of the inherent
limitations in all control systems, no evaluation of controls can provide absolute
assurance that all control issues and instances of fraud, if any, within Cerner have been
detected.
Table of Contents
Item 10.
Directors and Executive Officers of the Registrant
The Board of Directors has determined that Gerald E. Bisbee, Jr., Ph.D., a member of the Companys
Audit Committee, is an audit committee financial expert as that term is defined under Item 401(h)
of Regulation S-K.
The Board of Directors of the Company has adopted a Code of Conduct that applies to the Companys
principal executive officer, principal financial officer, controller and all other associates of
the Company, including its directors and other officers. The Company has posted the text of the
Code of Conduct on its website at
www.cerner.com
under About Cerner/Investors/Corporate
Governance.
Item 11.
Executive Compensation
Table of Contents
Item 12.
Security Ownership of Certain Beneficial Owners and Management
Item 13.
Certain Relationships and Related Transactions
Item 14.
Principal Accountant Fees and Services
Table of Contents
Item 15.
Exhibits and Financial Statement Schedules
(a)
Financial Statements and Exhibits.
(2)
The following financial statement schedule and Report of Independent Registered Public Accounting Firm of the Registrant for the three-year period ended
January 1, 2005 are included herein:
Schedule II Valuation and Qualifying Accounts,
Report of Independent Registered Public Accounting Firm
All other schedules are omitted, as the required information is inapplicable
or the information is presented in the consolidated financial statements or
related notes.
(3)
The exhibits required to be filed by this item are set forth
below:
Number
Description
Second Restated Certificate of Incorporation of the Registrant, dated December 5, 2003 (filed
as exhibit 3(a) to Registrants Annual Report on Form 10-K for the year ended January 3, 2004,
and incorporated herein by reference).
Amended and Restated Bylaws, dated March 9, 2001 (filed as Exhibit 4.2 to Registrants Form
S-8 filed on September 26, 2001 and incorporated herein by reference).
Amended and Restated Rights Agreement, dated as of March 12, 1999, between Cerner Corporation
and UMB Bank, n.a., as Rights Agents, which includes the Form of Certificate of Designation,
Preferences and Rights of Series A Preferred Stock of Cerner Corporation, as Exhibit A, and
the Form of Rights Certificate, as Exhibit B (filed as an Exhibit to Registrants current
report on Form 8-A/A dated March 31, 1999 and incorporated herein by reference).
Table of Contents
Number
Description
Specimen stock certificate (filed as Exhibit 4(a) to Registrants Registration Statement on
Form S-8 (File No. 33-15156) and hereby incorporated herein by reference).
Credit Agreement between Cerner Corporation and U.S. Bank National Association as
administrative agent and head arranger, and LaSalle Bank National Association, as document
agent, dated as of May 31, 2002 (filed as Exhibit 4(a) to Registrants Quarterly Report on
Form 10-Q for the quarter ended June 29, 2002, and incorporated herein by reference).
First Amendment to Credit Agreement between Cerner Corporation and U.S. Bank National
Association as administrative agent and head arranger, and LaSalle Bank National Association,
as documentation agent, dated as of July 22, 2002 (filed as Exhibit 4(d) to Registrants
Annual Report on Form 10-K for the year ended December 28, 2002, and incorporated herein by
reference).
Second Amendment to Credit Agreement between Cerner Corporation and U.S. Bank National
Association as administrative agent and head arranger, and LaSalle Bank National Association,
as documentation agent, dated as of July 22, 2002 (filed as Exhibit 4(f) to Registrants
Quarterly Report on From 10-A for the quarter ended June 28, 2003, and incorporated herein by
reference).
Third Amendment to Credit Agreement between Cerner Corporation and U.S. Bank National
Association as administrative agent and head arranger, and LaSalle Bank National Association,
as documentation agent, dated as of September 1, 2004 (filed as Exhibit 99.1 to Registrants
Form 8-K filed on September 8, 2004, and incorporated herein by reference).
Fourth Amendment to Credit Agreement between Cerner Corporation and U.S. Bank National
Association as administrative agent and head arranger, and LaSalle Bank National Association,
as documentation agent, dated as of December 28, 2004 (filed as Exhibit 99.1 to Registrants
Form 8-K filed on January 4, 2005, and incorporated herein by reference).
Cerner Corporation Note Agreement dated as of April 1, 1999 among Cerner Corporation,
Principal Life Insurance Company, Principal Life Insurance Company, on behalf of one or more
separate accounts, Commercial Union Life Insurance Company of America, Nippon Life Insurance
Company of America, John Hancock Mutual Life Insurance Company, John Hancock Variable Life
Insurance Company, and Investors Partner Life Insurance Company (filed as Exhibit 4(e) to
Registrants Form 8-K dated April 23, 1999, and incorporated herein by reference).
Incentive Stock Option Plan C of Registrant (filed as Exhibit 10(f) to Registrants Annual
Report on Form 10-K for the year ended December 31, 1993, and incorporated herein by
reference).*
Indemnification Agreements between the Registrant and Neal L. Patterson, Clifford W. Illig
and Gerald E. Bisbee, Jr., Ph.D. (filed as Exhibit 10(i) to Registrants Annual report on Form
10-K for the year ended December 31, 1992, and incorporated herein by reference).*
Indemnification Agreement between Michael E. Herman and Registrant (filed as Exhibit
10(i)(a) to Registrants Quarterly Report on Form 10-Q for the year ended June 29, 1996 and
incorporated herein by reference).*
Indemnification Agreement between John C. Danforth and Registrant (filed as Exhibit 10(i)(b)
to Registrants Quarterly Report on Form 10-Q for the year ended June 29, 1996 and
incorporated herein by reference).*
Table of Contents
Number
Description
Indemnification Agreement between John C. Danforth and Registrant dated February 3, 2005
(filed as Exhibit 99.1 to the Registrants Form 8-K dated February 3, 2005 and incorporated
herein by reference).*
Indemnification Agreement between Jeff C. Goldsmith, Ph.D. and Registrant (filed as Exhibit
10(e) to Registrants Annual Report on Form 10-K for the year ended January 1, 2000 and
incorporated herein by reference).*
Indemnification Agreement between William B. Neaves, Ph.D. and Nancy-Ann DeParle and
Registrant (filed as Exhibits 10.1 and 10.2 to Registrants Form 10-Q for the quarter ended
September 29, 2001 and incorporated herein by reference).*
Amended Stock Option Plan D of Registrant as of December 8, 2000 (filed as Exhibit 10(f) to
Registrants Annual Report on Form 10-K for the year ended December 30, 2000, and incorporated
herein by reference).*
Amended Stock Option Plan E of Registrant as of December 8, 2000 (filed as Exhibit 10(g) to
Registrants Annual Report on Form 10-K for the year ended December 30, 2000, and incorporated
herein by reference).*
Long-Term Incentive Plan for 1999 (filed as Exhibit 10(l) to Registrants Annual Report on
Form 10-K for the year ended January 2, 1999, and incorporated herein by reference).*
Cerner Corporation Executive Stock Purchase Plan (filed as Exhibit 4(g) to Registrants
Registration Statement on Form S-8 (File No. 333-77029) and incorporated herein by
reference).*
Form of Stock Pledge Agreement for Cerner Corporation Executive Stock Purchase Plan (filed
as Exhibit 4(h) to Registrants Registration Statement on Form S-8 (File No. 333-77029) and
incorporated herein by reference).*
Form of Promissory Note for Cerner Corporation Executive Stock Purchase Plan (filed as
Exhibit 4(i) to Registrants Registration Statement on Form S-8 (File No. 333-77029) and
incorporated herein by reference).*
Employment Agreement of Earl H. Devanny, III (filed as Exhibit 10(q) to Registrants Annual
Report on Form 10-K for the year ended January 1, 2000, and incorporated herein by
reference).*
Cerner Corporation 2001 Long-Term Incentive Plan F (filed as Annex I to Registrants 2001
Proxy Statement and incorporated herein by reference).*
Cerner Corporation 2004 Long-Term Incentive Plan G (filed as Annex I to Registrants 2004
Proxy Statement and incorporated herein by reference).*
Cerner Corporation 2001 Associate Stock Purchase Plan (filed as Annex II Registrants 2001
Proxy Statement and incorporated herein by reference).*
Qualified Performance-Based Compensation Plan (filed as Exhibit 10(v) to Registrants Annual
Report on Form 10-K for the year ended December 30, 2000, and incorporated herein by
reference).*
Note Purchase Agreement between Cerner Corporation and the purchasers therein, dated
December 15, 2002 (filed as Exhibit 10(x) to Registrants Annual Report on Form 10-K for the
year ended December 28, 2002, and incorporated herein by reference).
Table of Contents
Number
Description
Cerner Corporation Executive Deferred Compensation Plan (filed as Exhibit 10(y) to
Registrants Annual Report on Form 10-K for the year ended December 28, 2002, and incorporated
herein by reference).
Cerner Corporation Enhanced Severance Pay Plan and Summary Plan Description dated October
14, 2003. (filed as Exhibit 10(a) to Registrants Quarterly Report on Form 10-Q for the
quarter ended June 28, 2003, and is incorporated herein by reference).
Cerner Corporation 2001 Long-Term Incentive Plan F Nonqualified Stock Option Agreement. *
Cerner Corporation 2001 Long-Term Incentive Plan F Nonqualified Stock Option Director
Agreement. *
Cerner Corporation 2001 Long-Term Incentive Plan F Director Restricted Stock Agreement.*
2005 Executive Cerner Performance Plan. *
Management contracts or compensatory plans or arrangements required to be identified by
Item15(a)(3)(b)
Computation of Registrants Earnings Per Share. (Exhibit omitted. Information contained in
notes to consolidated financial statements.)
Subsidiaries of Registrant.
Consent of Independent Registered Public Accounting Firm
Certification of Neal L. Patterson, Chairman of the Board and Chief Executive Officer,
pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Marc G. Naughton, Chief Financial Officer, pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
Certification pursuant to 18 U.S.C. Section. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
Certification pursuant to 18 U.S.C. Section. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
(b)
Exhibits.
The response to this portion of Item 15 is submitted as a separate section of this report.
(c)
Financial Statement Schedules.
The response to this portion of Item 15 is submitted as a separate section of this
report.
Table of Contents
CERNER CORPORATION
By:
/s/ Neal L. Patterson
Neal L. Patterson
Chairman of the Board and Chief Executive Officer
Signature and Title
Date
March 17, 2005
Officer (Principal Executive Officer)
March 17, 2005
March 17, 2005
Officer (Principal Financial and Accounting Officer)
March 17, 2005
March 17, 2005
March 17, 2005
March 17, 2005
March 17, 2005
March 17, 2005
Table of Contents
Cerner Corporation:
March 11, 2005
Table of Contents
Cerner Corporation:
March 11, 2005
Table of Contents
(In thousands except shares and per share data)
2004
2003
$
189,784
121,839
282,199
256,574
7,373
12,434
30,117
33,044
509,473
423,891
230,440
204,953
157,765
141,090
54,600
51,573
22,690
24,036
7,297
8,709
$
982,265
854,252
$
37,008
20,753
21,908
21,162
77,445
64,879
430
15,586
55,819
45,004
6,634
10,095
199,244
177,479
108,804
124,570
69,863
54,412
5,703
1,945
1,166
1,166
381
371
271,116
236,969
344,011
279,363
(26,793
)
(26,793
)
8,770
4,770
597,485
494,680
$
982,265
854,252
Table of Contents
(In thousands, except per share data)
2004
2003
2002
$
351,861
332,349
332,274
542,414
476,795
419,578
32,081
30,443
28,410
926,356
839,587
780,262
196,348
194,290
190,550
383,628
352,728
319,265
171,589
156,236
129,620
63,327
58,236
50,007
814,892
761,490
689,442
111,464
78,097
90,820
(6,152
)
(7,017
)
(5,555
)
2,608
142
87
5,177
(9,904
)
(3,544
)
(6,875
)
(10,195
)
107,920
71,222
80,625
(43,272
)
(28,431
)
(31,817
)
64,648
42,791
48,808
(786
)
$
64,648
42,791
48,022
$
1.79
1.21
1.38
(0.02
)
$
1.79
1.21
1.36
$
1.72
1.18
1.32
(0.02
)
$
1.72
1.18
1.30
Table of Contents
Additional
Treasury
Accumulated
Other
Common Stock
paid-in
Retained
stock
Comprehensive
Comprehensive
(In thousands)
Shares
Amount
capital
Earnings
amount
Income
Income
36,565
$
366
216,811
188,550
(20,799
)
9,911
168
1
3,259
(64
)
90
1,561
(609
)
5,800
427
427
(76
)
(76
)
(12,006
)
(12,006
)
48,022
48,022
36,367
36,733
$
367
226,912
236,572
(20,863
)
(1,744
)
324
4
6,699
(5,930
)
34
1,876
(604
)
2,052
6,438
6,438
76
76
42,791
42,791
49,305
37,057
$
371
236,969
279,363
(26,793
)
4,770
1,083
10
25,535
173
9,191
(752
)
4,000
4,000
64,648
64,648
68,648
38,140
$
381
271,116
344,011
(26,793
)
8,770
Table of Contents
(In thousands)
2004
2003
2002
$
64,648
42,791
48,022
90,802
69,330
57,346
(3,023
)
9,904
(5,177
)
1,272
34
90
295
21,317
8,710
(31,200
)
9,191
1,876
1,561
(24,747
)
20,723
(50,364
)
3,924
(3,393
)
(2,762
)
(20,743
)
(201
)
(13,302
)
9,474
(30,663
)
20,648
15,919
(5,187
)
1,791
16,055
22,561
(12,203
)
6,509
(5,038
)
2,570
103,656
91,359
(11,116
)
168,304
134,150
36,906
(44,214
)
(26,831
)
(33,235
)
(12,276
)
(56,752
)
(26,464
)
(1,957
)
(6,380
)
(26,016
)
12,000
95,134
(156
)
1,977
651
451
(58,912
)
(58,736
)
(49,984
)
(103,382
)
(148,048
)
(40,270
)
320
70,102
(24,879
)
(13,238
)
(41,032
)
2,052
5,800
(5,930
)
25,717
6,703
3,196
(752
)
(604
)
(609
)
86
(10,697
)
37,457
2,937
3,740
914
151
67,945
(20,704
)
35,007
121,839
142,543
107,536
$
189,784
121,839
142,543
$
8,614
7,984
6,937
21,865
10,426
49,484
$
7,500
2,075
9,811
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Table of Contents
Weighted
January 1, 2005
January 3, 2004
Average
Gross
Gross
Amortization
Carrying
Accumulated
Carrying
Accumulated
Period (Yrs)
Amount
Amortization
Amount
Amortization
5.0
$
40,966
20,792
36,236
14,683
7.0
3,700
2,240
3,700
1,711
14.0
1,080
109
552
86
5.0
125
40
50
22
5.37
$
45,871
23,181
40,538
16,502
2005
$
8,244
2006
6,454
2007
4,535
2008
2,414
2009
689
$
51,573
8,822
(6,513
)
718
$
54,600
Table of Contents
2004
2003
2002
$
64,648
42,791
48,022
(7,903
)
(13,392
)
(16,640
)
56,745
29,399
31,382
$
1.79
1.21
1.36
(.22
)
(.38
)
(.47
)
1.57
.83
.89
$
1.72
1.18
1.30
(.21
)
(.37
)
(.45
)
1.51
.81
.85
Table of Contents
Table of Contents
Entity Name, Description of Business
Developed
Form of
Acquired, and Reason Business Acquired
Date
Consideration
Goodwill
Technology
Consideration
ICU performance analysis and benchmarking
Integrate technology into
Cerner Millennium
2/04
$
.3
$
.7
$
.6
$.3 cash
Laboratory information management and
logistics
Integrate technology into
Cerner Millennium
8/04
$
1.5
$
.6
$
.8
$1.5 cash
Home care technologies
Integrate technology into
Cerner Millennium
9/03
$
7.5
$
3.0
$
3.2
$7.5 cash
Picture archiving and communication system
software
Supplier of the image archive component for
Cerner ProVision TM
PACS
10/02
$
15.7
$
11.9
$
4.4
$14.3 cash
$1.4 note payable
Solutions and services that deliver the
latest scientific knowledge and best
practices
Integrate technology into
Cerner Millennium
4/02
$
15.0
$
10.4
$
3.3
$17.5 cash
$5 note
payable
Project IMPACT
Gajema
BeyondNow
Image Devices
Zynx Health
CCM, Inc.
Software
Technologies
GmbH
Incorporated
644,000
72,000
1,977,000
1,603,000
2,656,000
1,867,000
1,551,000
8,170,000
18,007,000
16,949,000
1,050,000
51,000
714,000
4,205,000
1,420,000
1,201,000
51,000
714,000
4,205,000
1,669,000
Table of Contents
(In thousands)
2004
2003
$
185,290
162,234
96,909
94,340
$
282,199
256,574
(In thousands)
Depreciable lives
2004
2003
5 12 yrs
$
46,567
43,441
5 yrs
197,352
150,600
5 yrs
2,649
2,649
5 yrs
2,902
2,902
2 15 yrs
61,190
52,378
3 5 yrs
14,836
13,087
12 50 yrs
95,029
93,006
420,525
358,063
190,085
153,110
$
230,440
204,953
Table of Contents
Table of Contents
$
21,908
28,558
20,207
14,373
16,417
29,249
$
130,712
(In thousands)
2004
2003
2002
$
3,022
1,219
1,080
(9,174
)
(8,236
)
(6,635
)
$
(6,152
)
(7,017
)
(5,555
)
Table of Contents
Table of Contents
2004
2003
2002
Weighted-
Weighted-
Weighted-
Number
average
Number
average
Number
average
Of
exercise
Of
exercise
of
exercise
Fixed options
Shares
price
Shares
price
shares
price
8,143,614
$
30.29
8,080,864
$
31.28
7,244,224
$
28.79
893,793
44.64
951,917
26.43
1,501,729
43.50
(1,082,517
)
23.64
(324,622
)
20.70
(167,092
)
19.40
(682,316
)
36.05
(564,545
)
41.16
(497,997
)
36.17
7,275,574
$
32.50
8,143,614
$
30.37
8,080,864
$
31.28
3,493,467
$
31.44
3,239,586
$
26.89
2,512,357
$
24.94
Options outstanding
Options exercisable
Range of
Number
Weighted-average
Number
Exercise
outstanding
remaining
Weighted-average
exercisable
Weighted-average
Prices
at 1/1/05
contractual life
exercise price
at 1/1/05
exercise price
$ 11.06-22.95
2,319,198
11.09 years
$
18.05
1,112,774
$
16.94
22.63-37.36
1,892,833
8.16
28.59
1,033,835
27.59
37.40-46.23
2,281,610
6.70
43.51
1,002,587
43.82
46.60-273.72
781,933
7.42
52.71
344,271
53.73
11.06-273.72
7,275,574
8.55
32.50
3,493,467
31.44
2004
2003
2002
6.5
6.5
6.5
4.0
%
3.8
%
3.4
%
67.3
%
71.2
%
68.7
%
0
%
0
%
0
%
Table of Contents
(In thousands)
2004
2003
2002
$
37,524
9,808
49,384
6,756
1,790
5,699
(1,303
)
(4,484
)
(1,262
)
42,977
7,114
53,821
1,712
19,040
(21,676
)
174
2,806
(1,245
)
(1,591
)
(529
)
431
295
21,317
(22,490
)
$
43,272
28,431
31,331
(In thousands)
2004
2003
Deferred Tax Assets
$
13,673
9,920
8,004
10,442
3,754
5,024
25,431
25,386
(61,146
)
(55,291
)
(13,526
)
(25,096
)
(20,825
)
(14,279
)
(227
)
(718
)
(95,724
)
(95,384
)
$
(70,293
)
(69,998
)
Table of Contents
(In thousands)
2004
2003
2002
$
37,772
24,928
27,774
3,507
2,315
2,579
442
793
364
1,551
395
614
$
43,272
28,431
31,331
Table of Contents
Years
Aggregate
minimum
future
payments
$ 16,614
12,234
6,428
4,964
3,577
6,634
Table of Contents
Operating Segments
Great
Mid-
North
South-
2004
Lakes
America
Atlantic
east
West
Global
Other
Total
$
157,627
$
201,570
$
179,520
$
148,186
$
150,694
$
64,333
$
24,426
$
926,356
29,805
32,588
41,050
35,487
28,577
8,938
19,903
196,348
27,689
31,618
30,487
33,267
33,827
38,411
423,245
618,544
57,494
64,206
71,537
68,754
62,404
47,349
443,148
814,892
$
100,133
$
137,364
$
107,983
$
79,432
$
88,290
$
16,984
$
(418,722
)
$
111,464
Operating Segments
Great
Mid-
North
South-
2003
Lakes
America
Atlantic
east
West
Global
Other
Total
$
153,949
$
160,633
$
149,585
$
145,312
$
161,840
$
54,191
$
14,077
$
839,587
36,910
35,447
37,520
40,784
28,321
13,450
1,858
194,290
24,897
24,815
26,788
29,454
28,223
35,814
397,209
567,200
61,807
60,262
64,308
70,238
56,544
49,264
399,067
761,490
$
92,142
$
100,371
$
85,277
$
75,074
$
105,296
$
4,927
$
(384,990
)
$
78,097
Table of Contents
Earnings
before income taxes
and cumulative
Basic
Diluted
effect of a change in
Net
earnings
Earnings
(In thousands, except per share data)
Revenues
accounting principle
earnings
per share
per share
$
218,728
23,412
14,129
.40
.38
228,390
23,940
14,314
.40
.38
231,067
24,823
14,779
.41
.39
248,171
35,745
21,426
.59
.56
$
926,356
107,920
64,648
$
198,191
9,418
5,593
.16
.15
207,695
14,871
8,943
.25
.25
206,292
20,046
12,047
.34
.33
227,409
26,887
16,208
.46
.44
$
839,587
71,222
42,791
(1)
Includes a gain on the sale of Zynx Health Incorporated. The impact of this gain
is a $1.8 million increase, net of $1.2 million tax expense, in net earnings and
increase to diluted earnings per share of $.05 for the first quarter and for 2004.
(2)
Includes a charge for vacation accrual of $3.3 million included in general
and administrative. The impact of this charge is a $2.1 million decrease, net of $1.2
million tax benefit, in net earnings and a decrease to diluted earnings per share of
$.06 for the third quarter and for 2004.
Table of Contents
Valuation and Qualifying Accounts
Additions
Balance at
Charged to
Additions
Beginning
Costs and
Through
Balance at
Description
of Period
Expenses
Acquisitions
Deductions
End of Period
$
6,880,000
$
2,816,000
$
597,000
$
(791,000
)
$
9,502,000
Additions
Through
Additions
Acquisitions and
Balance at
Charged to
Consolidation of
Beginning
Costs and
Variable Interest
Balance at
Description
of Period
Expenses
Entity
Deductions
End of Period
$
9,502,000
$
6,017,000
$
1,331,000
$
(4,794,000
)
$
12,056,000
Additions
Balance at
Charged to
Additions
Beginning
Costs and
Through
Balance at
Description
of Period
Expenses
Acquisitions
Deductions
End of Period
$
12,056,000
$
8,144,000
$
$
(2,617,000
)
$
17,583,000
Table of Contents
Public Accounting Firm
Cerner Corporation:
March 11, 2005
CERNER CORPORATION 2001
LONG-TERM INCENTIVE PLAN F NONQUALIFIED STOCK OPTION DIRECTOR AGREEMENT
Exhibit 10(v)
(Continued from the "Front" of this certificate)
WITNESSETH: WHEREAS, the Plan F Stock Option Committee of the Board of Directors of the Company (the "Committee") has determined that the Optionee is eligible to receive an option to purchase shares of common stock of the Company under the Company's 2001 Long-Term Incentive Plan F (the "Plan"),
NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained and other good and valuable consideration, the parties hereto do hereby agree as follows:
1. INCORPORATION OF THE PLAN. A copy of the Plan is incorporated herein by reference and all of the terms, conditions and provisions contained therein shall be deemed to be contained in this Agreement.
2. GRANT OF OPTION. Pursuant to the authorization of the Committee, and subject to the terms, conditions and provisions contained in this Agreement, the Company hereby grants to the Optionee an option (the "Option") to purchase from the Company all or any part of an aggregate number of shares of Company common stock designated as "Option Shares" on the other side hereof ("Front") at a price per share equal to the Exercise Price on the Front. The date written on the Front shall be deemed to be the Granting Date of this Option.
3. TERM OF OPTION. The Optionee may purchase all or any portion of the shares subject to each installment listed in the Vesting Schedule on the Front hereof at any time on or after the Exercise Dates listed therein and before the Expiration Date (or any earlier termination date).
This Option shall expire with respect to all shares of Company common stock subject hereto ten (10) years from the Granting Date (the "Expiration Date"), unless it shall be terminated at an earlier date in accordance with this Agreement.
Except as specifically set forth below, this Option shall expire as to all Option Shares that are not yet vested or which are vested but not yet exercised as of the date (90) calendar days after termination of the Optionee's position as a Director on the Board of Directors of the Company (the "Board"). In the event such position is terminated by reason of the Optionee's death or disability the Optionee, or Optionee's estate, shall have one(1) year following such date of death or disability to exercise this Option as to the number of Option shares vested and exercisable or becoming vested within ninety (90) calender days of such date of death or disability. In the event such Optionee is removed from the Board for cause, pursuant to the Company's Bylaws, then all vested and unvested Option shares shall expire immediately upon removal of Optionee form the Board. In the event Optionee has assigned this Option, once vested, to First Hand Foundation, a Missouri nonprofit corporation, then such Option to purchase shall expire two (2) years from the date of the assignment.
In the event of (i)a dissolution or liquidation of the company, (ii) a merger
or consolidation in which the company is not the surviving corporation (other
than a merger of consolidation with a wholly-owned subsidiary, a
re-incorporation of the company in a different jurisdiction, or other
transaction in which there is no substantial change in the stockholders of the
company or their relative stock holdings and the options granted under this
Agreement are assumed, converted or replaced by the successor corporation),
(iii) a merger in which the company is the surviving corporation but after which
the stockholders of the company immediately prior to such merger (other than any
stockholder that merges,or which owns or controls onther corporation that
mergas, with the company in such merger) cease to own their shares or other
equity interest in the company, or (v) the acquisition, sale, or transfer of
more than 50% of the outstanding shares of the company by tender offer or
similar transaction, (i) through (v) being considered a "Change of Control"),
the options will become exercisable in full immediately prior to the
consummation of such transaction (provided, however, that no acceleration shall
occur if the optionee is part of the group that is attempting to initiate any of
the transactions described in this paragraph 3) and shall expire on the
Expiration Date.
4. EXERCISE OF OPTION. This Option may be exercised by Optionee delivering to the Company a written notice of exercise along with a payment in the amount of the Exercise Price for such shares plus the amount of any applicable federal, state, or local taxes to be withheld and remitted by the Company in connection with such exercise. The payment for the Exercise Price for the shares may be made: (a) In cash, or (b) by delivery to the Company of that number of shares of Cerner common stock having a fair market value on the date of exercise equal to the sum of the exercise price of the options to be exercised, as long as the shares delivered have been held by the Optionee for at least six (6) months. Payment for any applicable federal, state, or local taxes must be made in cash.
5. INVESTMENT PURPOSE. By accepting this Option, the Optionee agrees that any and all shares of stock purchased upon the exercise of this Option will be purchased for investment purposes, and not with a view to any distribution thereof, and that each notice of the exercise of any portion of this Option shall be accompanied by a representation in writing signed by the Optionee (or by the person or persons entitled to exercise the Option in the event of the death of the Optionee) that the shares of stock are being purchased in good faith for personal investment purposes, and not with a view to any distribution thereof.
When a registration statement filed with the Securities and Exchange Commission regarding the shares of common stock subject to this option agreement (the "Registration Statement") becomes effective, the investment representation contained in this section will no longer be applicable.
6. STOCK RESTRICTIONS. Until such time as the Registration Statement becomes effective, the Optionee further agrees that:
(a) Each stock certificate issued pursuant to the exercise of the Option granted hereby shall bear a legend to the effect that the shares represented thereby have not been registered under the Securities Act of 1933, and may not be transferred except in accordance with the provisions of this Agreement.
(b) The shares of the stock acquired upon the exercise of this Option may be transferred, in whole or in part, only if in the opinion of counsel for the Company such proposed transfer may be effected without registration under the Securities Act of 1933 and appropriate state securities laws or such registration has been effected. Prior to the transfer of any such shares the holder thereof shall furnish the Company written notice of the intention to effect such transfer, which notice shall include the manner and circumstances of the proposed transfer and such other matters as the Company may request. The Optionee shall promptly comply with any request by the Company for information concerning any disposition by the Optionee of any shares acquired pursuant to this Option which the Company may need in connection with an income tax return or any other return or report which it may be required to file with any governmental agency.
7. NOTICES. Any notices or other communications required or allowed to be made or given to the Company under the terms of this Agreement shall be addressed to the Company in care of its President at its offices at 2800 Rockcreek Parkway, North Kansas City, Missouri 64117, and any notice to be given to the Optionee shall be addressed to the Optionee at Optionee's address set forth on the Front of this Agreement. Either party hereto may from time to time change the address to which notices are to be sent to such party by giving written notice of such change to the other party. Any notice hereunder shall be deemed to have been duly given five business days after registered and deposited, postage and registry fee prepaid, in a post office regularly maintained by the United States Government.
8. BINDING EFFECT AND ASSIGNMENT. This Agreement shall bind the parties hereto but shall not be assignable by Optionee without the express written consent of Company, except that Optionee shall have the right to assign this Option, once vested, to First Hand Foundation, a Missouri nonprofit corporation, anytime during Optionee's service as a Director of the Company or within ninety (90) days of Optionee's termination as a Director of the Company, provided the Option has not terminated prior to such assignment. The Company will maintain records of all stock option grants and exercises. In the event this Agreement and such records do not agree, such records shall control.
9. GOVERNING LAW. This Agreement shall be construed in accordance with the laws of the State of Missouri.
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed on the Front by its officer hereunto duly authorized and its corporate seal to be hereunto affixed, and the Optionee has hereunto set hand on the Front as of the day and year written on the Front.
Exhibit 10(w)
CERNER CORPORATION 2001
LONG-TERM INCENTIVE PLAN F NONQUALIFIED STOCK OPTION DIRECTOR AGREEMENT
(Continued from the "Front" of this certificate)
WITNESSETH: WHEREAS, the Plan F Stock Option Committee of the Board of Directors of the Company (the "Committee") has determined that the Optionee is eligible to receive an option to purchase shares of common stock of the Company under the Company's 2001 Long-Term Incentive Plan F (the "Plan"); NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained and other good and valuable consideration, the parties hereto do hereby agree as follows:
1. INCORPORATION OF THE PLAN. A copy of the Plan is incorporated herein by reference and all of the terms, conditions and provisions contained therein shall be deemed to be contained in this Agreement.
2. GRANT OF OPTION. Pursuant to the authorization of the Committee, and subject to the terms, conditions and provisions contained in this Agreement, the Company hereby grants to the Optionee an option (the "Option") to purchase from the Company all or any part of an aggregate number of shares of Company common stock designated as "Option Shares" on the other side hereof ("Front") at a price per share equal to the Exercise Price on the Front. The date written on the Front shall be deemed to be the Granting Date of this Option.
3. TERM OF OPTION. The Optionee may purchase all or any portion of the shares subject to each installment listed in the Vesting Schedule on the Front hereof at any time on or after the Exercise Dates listed therein and before the Expiration Date (or any earlier termination date).
This Option shall expire with respect to all shares of Company common stock subject hereto ten (10) years from the Granting Date (the "Expiration Date"), unless it shall be terminated at an earlier date in accordance with this Agreement.
Except as specifically set forth below, this Option shall expire as to all Option Shares that are not yet vested or which are vested but not yet exercised as of the date ninety (90) calendar days after termination of the Optionee's position as a Director on the Board of Directors of the Company (the "Board"). In the event such position is terminated by reason of the Optionee's death or disability the Optionee, or Optionee's estate, shall have one (1) year following such date of death or disability to exercise this Option as to the number of Option shares vested and exercisable or becoming vested within ninety (90) calendar days of such date of death or disability. In the event such Optionee is removed from the Board for cause, pursuant to the Company's Bylaws, then all vested and unvested Option shares shall expire immediately upon removal of Optionee from the Board. In the event Optionee has assigned this Option, once vested, to First Hand Foundation, a Missouri nonprofit corporation, then such Option to purchase shall expire two (2) years from the date of the assignment.
In the event of (i) a dissolution or liquidation of the Company, (ii) a merger
or consolidation in which the Company is not the surviving corporation (other
than a merger or consolidation with a wholly-owned subsidiary, a
re-incorporation of the Company in a different jurisdiction, or other
transaction in which there is no substantial change in the stockholders of the
Company or their relative stock holdings and the Options granted under this
Agreement are assumed, converted or replaced by the successor corporation),
(iii) a merger in which the Company is the surviving corporation but after which
the stockholders of the Company immediately prior to such merger (other than any
stockholder that merges, or which owns or controls another corporation that
merges, with the Company in such merger) cease to own their shares or other
equity interest in the Company, (iv) the sale of substantially all of the assets
of the Company, or (v) the acquisition, sale, or transfer of more than 50% of
the outstanding shares of the Company by tender offer or similar transaction,
(i) through (v) being considered a "Change of Control"), the Options will become
exercisable in full immediately prior to the consummation of such transaction
(provided, however, that no acceleration shall occur if the Optionee is part of
the group that is attempting to initiate any of the transactions described in
this Paragraph 3)and shall expire on the Expiration Date.
4. EXERCISE OF OPTION. This Option may be exercised by Optionee delivering to the Company a written notice of exercise along with a payment in the amount of the Exercise Price for such shares plus the amount of any applicable federal, state, or local taxes to be withheld and remitted by the Company in connection with such exercise. The payment for the Exercise Price for the shares may be made: (a) In cash, or (b) by delivery to the Company of that number of shares of Cerner common stock having a fair market value on the date of exercise equal to the sum of the exercise price of the options to be exercised, as long as the shares delivered have been held by the Optionee for at least six (6) months. Payment for any applicable federal, state, or local taxes must be made in cash.
5. INVESTMENT PURPOSE. By accepting this Option, the Optionee agrees that any and all shares of stock purchased upon the exercise of this Option will be purchased for investment purposes, and not with a view to any distribution thereof, and that each notice of the exercise of any portion of this Option shall be accompanied by a representation in writing signed by the Optionee (or by the person or persons entitled to exercise the Option in the event of the death of the Optionee) that the shares of stock are being purchased in good faith for personal investment purposes, and not with a view to any distribution thereof.
When a registration statement filed with the Securities and Exchange Commission regarding the shares of common stock subject to this option agreement (the "Registration Statement") becomes effective, the investment representation contained in this section will no longer be applicable.
6. STOCK RESTRICTIONS. Until such time as the Registration Statement becomes effective, the Optionee further agrees that: (a) Each stock certificate issued pursuant to the exercise of the Option granted hereby shall bear a legend to the effect that the shares represented thereby have not been registered under the Securities Act of 1933, and may not be transferred except in accordance with the provisions of this Agreement.
(b) The shares of the stock acquired upon the exercise of this Option may be transferred, in whole or in part, only if in the opinion of counsel for the Company such proposed transfer may be effected without registration under the Securities Act of 1933 and appropriate state securities laws or such registration has been effected. Prior to the transfer of any such shares the holder thereof shall furnish the Company written notice of the intention to effect such transfer, which notice shall include the manner and circumstances of the proposed transfer and such other matters as the Company may request. The Optionee shall promptly comply with any request by the Company for information concerning any disposition by the Optionee of any shares acquired pursuant to this Option which the Company may need in connection with an income tax return or any other return or report which it may be required to file with any governmental agency.
7. NOTICES. Any notices or other communications required or allowed to be made or given to the Company under the terms of this Agreement shall be addressed to the Company in care of its President at its offices at 2800 Rockcreek Parkway, North Kansas City, Missouri 64117, and any notice to be given to the Optionee shall be addressed to the Optionee at the Optionee's addressset forth on the Front of this Agreement. Either party hereto may from time to time change the address to which notices are to be sent to such party by giving written notice of such change to the other party. Any notice hereunder shall be deemed to have been duly given five business days after registered and deposited, postage and registry fee prepaid, in a post office regularly maintained by the United States Government.
8. BINDING EFFECT AND ASSIGNMENT. This Agreement shall bind the parties hereto but shall not be assignable by Optionee without the express written consent of Company, except that Optionee shall have the right to assign this Option, once vested, to First Hand Foundation, a Missouri nonprofit corporation, anytime during Optionee's service as a Director of the Company or within ninety (90) days of Optionee's termination as a Director of the Company, provided the Option has not terminated prior to such assignment. The Company will maintain records of all stock option grants and exercises. In the event this Agreement and such records do not agree, such records shall control.
9. GOVERNING LAW. This Agreement shall be construed in accordance with the laws of the State of Missouri.
IN WITNESS WHEREOF, the Company has caused this Agreement to be executed on the Front by its officers hereunto duly authorized and its corporate seal to be hereunto affixed, and the Optionee has hereunto set hand on the Front as of the day and year written on the Front.
CERNER CORPORATION 2001
LONG-TERM INCENTIVE PLAN F DIRECTOR RESTRICTED STOCK AGREEMENT
Exhibit 10(x)
(Continued from the "Front" of this Notice of Grant document)
WHEREAS, the Compensation Committee (the "Committee") of the Board of Directors of Cerner Corporation ("the Company") has determined that ____________[name] (the "Participant") is eligible to receive a Restricted Stock Grant under the Company's 2001 Long-Term Incentive Plan F (the "Plan"), as so indicated on the Front;
NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained and other good and valuable consideration, the parties hereto do hereby agree as follows:
1. INCORPORATION OF THE PLAN. A copy of the Plan is incorporated herein by reference and all the terms, conditions and provisions contained therein shall be deemed to be contained in this Agreement.
2. RESTRICTED STOCK GRANT. Pursuant to the authorization of the Committee, and subject to the terms, conditions and provisions contained in this Agreement, the Company hereby grants to the Participant a Restricted Stock Award (the "Award") for the aggregate number of shares of Company common stock (the "Shares") set forth on the front or first page of this Agreement (the "Front"). The date of grant of the Award (the "Grant Date") shall for all purposes be as set forth on the Front.
3. RIGHTS AS A SHAREHOLDER. Commencing on the Grant Date, the Participant shall
have the right to receive dividends and other distributions (if any) with
respect to the Shares unless and until such shares are forfeited pursuant to
Section 5 hereof; provided, however, that a dividend or other distribution
(including, without limitation, a stock dividend or stock split), other than a
cash dividend or distribution, shall be delivered to the Company and shall be
subject to the same vesting schedule and other terms, conditions and
restrictions as the Shares with respect to which such dividend or other
distribution was made. In connection with the payment of such dividends or other
distributions, the Company may deduct any taxes or other amounts required by any
governmental authority to be withheld and paid over to such authority for the
account of the Participant. The Participant shall be entitled to retain cash
dividends and distributions received regardless of whether the Shares with
respect to which such dividends or distributions were made are subsequently
forfeited pursuant to Section 5 hereof. Participant shall have no right to vote
the Shares until such Shares are actually issued on the Vest Date.
Notwithstanding anything to the contrary, prior to the date on which the Shares
and any related property received under Section 3 hereof (the "Aggregate
Restricted Shares") Vest pursuant to Section 5, such Aggregate Restricted Shares
shall be subject to the restrictions on transferability contained in Section 6
hereof.
4. CUSTODY AND DELIVERY OF SHARES. Unless otherwise requested by Participant, Aggregate Restricted Shares will be issued in street name on the Vest Date and held in the Participant's account at Citigroup Global Markets Inc. d/b/a Smith Barney or other broker that the Company may choose (the "Broker"). Prior to the Vest Date, the Grant of the Aggregate Restricted Shares will be recorded in the Company's books and records. Company will reflect in its records the restrictions under which the Aggregate Restricted Shares are held and will not allow issuance or transfer of any Aggregate Restricted Shares prior to the date on which such Aggregate Restricted Shares Vest pursuant to Section 5 below. Share certificates representing Vested Aggregate Restricted Shares will be issued only on or after the Vest Date and only if the requirements of vesting set forth in Section 5 are met. The Company will pay all original issue or transfer taxes and all fees and expenses incident to the delivery of any Aggregate Restricted Shares hereunder.
5. VESTING AND FORFEITURE. Except as otherwise provided in the Plan or this Agreement, the Aggregate Restricted Shares subject to this Award shall issue, become transferable and shall cease to be subject to forfeiture ("Vest") on the date set forth on the Front (the "Vest Date") provided Participant has continuously served as a member of the Cerner Board of Directors (the "Board") from the Grant Date through the Vest Date set forth on the Front. In the event of the death or disability (preventing further Board service) of the Participant prior to the Vest Date, and assuming the Participant continuously served as a Director on the Board through the date of such death or disability, then the Aggregate Restricted Shares shall Vest on the Vest Date if the Vest Date occurs within ninety (90) days of such death or disability; otherwise the Aggregate Restricted Shares shall immediately terminate and be forfeited to the Company upon such death or disability. In the event such Participant is removed from the Board for cause, pursuant to the Company's Bylaws, or resigns from the Board, then all Aggregate Restricted Shares that have not Vested as of such date shall immediately terminate and shall be forfeited to the Company. In the event of a "Change of Control" as defined in the Plan, all restrictions upon the Aggregate Restricted Shares shall lapse, and all such shares shall immediately Vest upon such Change of Control.
6. NON-TRANSFERABILITY OF SHARES. Prior to the date on which Aggregate Restricted Shares Vest pursuant to Section 5 hereof, such Aggregate Restricted Shares may not be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process. Any such attempted sale, transfer, assignment, pledge, hypothecation or encumbrance, or other disposition of such Aggregate Restricted Shares shall be null and void.
7. SECURITIES LAWS. Participant hereby represents and covenants that if in the future the Participant decides to offer or dispose of any Aggregate Restricted Shares or interest therein, the Participant will do so only in compliance with this Agreement, the Securities Act of 1933, as amended, and all applicable state securities laws. As a condition precedent to the delivery to Participant of the Aggregate Restricted Shares, Participant shall comply with all regulations and requirements of any regulatory authority having control or supervision over the issuance of the Aggregate Restricted Shares and, in connection therewith, shall execute any documents and make any representation and warranty to the Company which the Committee shall in its sole discretion deem necessary or advisable.
8. TAXABLE INCOME. Participant may file an election for immediate Federal income taxation pursuant to Section 83(b) of the Internal Revenue Code. In the event that Participant makes an election pursuant to Section 83(b) of the Code, Participant agrees to notify the Company thereof in writing within ten (10) days after such election.
THE FEDERAL INCOME TAX CONSEQUENCES DESCRIBED ABOVE ARE FOR GENERAL INFORMATION ONLY. EACH PARTICIPANT SHOULD CONSULT A TAX ADVISOR AS TO THE SPECIFIC FEDERAL INCOME TAX CONSEQUENCES AND AS TO THE SPECIFIC CONSEQUENCES UNDER STATE, LOCAL AND FOREIGN TAX LAWS.
9. NOTICES. Any notices or other communications required or allowed to be made
or given to the Company under the terms of this Agreement shall be addressed to
the Company in care of its President at its offices at 2800 Rockcreek Parkway,
North Kansas City, Missouri 64117, and any notice to be given to the Participant
shall be addressed to the Participant at the address set forth on the Front.
Either party hereto may from time-to-time change the address to which notices
are to be sent to such party by giving written notice of such change to the
other party. Any notice hereunder shall be deemed to have been duly given five
(5) business days after registered and deposited, postage and registry fee
prepaid, in a post office regularly maintained by the United States government.
10. BINDING EFFECT AND ASSIGNMENT. This Agreement shall bind the parties hereto, but shall not be assignable by Participant.
11. GOVERNING LAW. This Agreement shall be construed in accordance with the laws of the State of Missouri.
This Agreement has been issued by the Company by its duly authorized representatives and shall be effective as of the day and year written on the
Front.
EXHIBIT 10(y)
2005 CERNER PERFORMANCE PLAN
<<FIRST>> <<LAST>>
CORPORATE EXECUTIVE
DOCUMENT OVERVIEW
This document describes Cerner's structured approach to determining incentive payments. This document is specific to the Plan type and individual noted above and contains information specific to the administration of this particular Plan.
PLAN PURPOSE
This Plan is intended to align performance incentives with the current business imperatives to drive business results in 2005. Success on the following corporate imperatives will create value for Associates, clients and shareholders: Grow the Top Line, Expand Operating Margin and Free Cash Flow, Create Innovation, Deliver the Cerner Experience to the Client and Associate. The Plan metrics below reflect the fact that it is essential for the Associate to drive results in his/her area of accountability which ensure corporate success.
PLAN METRICS
Your annual Target Bonus Level (TBL) is $<<Total_TBL>>. Your total opportunity will be comprised of the following metrics:
WEIGHTING METRICS TIMING CODE IC APPLIES SCOPE --------- ------- ----------- ---------- ----- EARNINGS PER SHARE Y YES CASH FLOW E YES OPERATING EARNINGS Y YES OPERATING MARGIN S YES PRODUCTIVITY MEASURES VARIABLE YES AGREEMENT MARGIN N YES DIVERSIFICATION OF BUSINESS OPPORTUNITIES A YES |
INDIVIDUAL CONTRIBUTION (IC) FACTOR
An additional factor that will be included in the incentive calculation is the Individual Contribution (IC) rating. Each Associate on CPP will receive a quarterly and an annual IC rating. This rating will be determined by contributions such as, but not limited to:
- Delivery of additional business results not captured by specific CPP metrics;
- "How" business results are achieved;
- Key Client Losses/Wins;
- Recruiting exceptional talent and building harvestable teams;
- Unique and substantial contributions to methodologies, capabilities, or intellectual property; and
- Collaboration and leadership of initiatives beyond your primary responsibilities.
The Individual Contribution percentage will be determined and applied as shown in the table below. Quarterly Individual Contribution ratings will only be applied for a rating less than "Highly Valued." Annual Individual Contribution ratings (collected following the fourth quarter) will be applied to an Associate's entire year's earnings according to the table on the following page.
INDIVIDUAL CONTRIBUTION FACTOR TABLE
PAGE 1 EFFECTIVE DATE: JANUARY 1, 2005
IC Bonus IC Factor Opportunity* ---------- ------------ Distinguished 130% <<TBL*30%>> <-Maximum IC Payout** Outstanding 120% <<TBL*20%>> Highly Valued 100% $0 <-Typical IC Payout New to Role*** 0% - 100% $0 Needs Development*** 25-75% <<TBL*-25%>> Unacceptable*** 0% <<-TBL>> |
TBL is your payout at 100% attainment of objectives before the IC Bonus Opportunity.
*These amounts will be adjusted to reflect actual attainment of objective performance targets, for your Rewardable Events plan metrics and changes, if any, in your Target Bonus Level.
**This amount plus your Target Bonus Level will equal your maximum bonus amount, which may also be adjusted upward or downward to reflect actual attainment of objective performance targets.
***All associates will be reviewed on a quarterly basis to determine the appropriateness of a CPP incentive payment prior to any distribution. Associates with New to Role, Needs Development or Unacceptable ratings will have these adjustments applied to quarterly CPP incentive payments. These payments are at the discretion of Cabinet.
PAYMENT TERMS, SCHEDULE AND CRITERIA
TERMS
Changes in an Associate's TBL will be reflected in payment calculations on a pro-rata basis for the appropriate quarters.
The year-end calculation of payments will not affect amounts earned for previous quarters; however, the actual Individual Contribution adjustment, if applicable, will apply to incentives earned for the full year.
Corrections to prior period payments may be made to ensure accurate incentive payment.
SCHEDULE
Payment of incentives will be made approximately sixty (60) days after the end of a quarter.
CRITERIA
1. In order to be eligible for any payments under this Plan, Cerner must have received the Associate's signed Cerner Associate Employment Agreement, which governs the terms of the Associate's employment at Cerner. CPP payments are contingent upon the Associate's completion of performance reviews as required by Cerner's Human Resources department.
2. Participation in this Plan begins as of the beginning of the first full quarter of employment in, or assignment to, a CPP-eligible role. Newly eligible Associates will satisfy the "full quarter" requirement as long as they are actively working within the first fifteen (15) working days of the quarter.
3. Participating Associates who are not actively at work for more than six
(6) weeks of any quarter may be deemed ineligible to earn incentives
during that quarter per the CPP Leave Policy located on myCerner.
OTHER PLAN CONSIDERATIONS
1. Termination of Participation: An Associate's participation in CPP is terminated immediately in the event of termination of employment or transfer to a non-CPP eligible role. The Associate will be entitled to payment for any earned but not paid amounts. Payments are earned only for completed quarters; i.e., if participation is terminated at any time before the completion of a quarter, no incentive will be paid for that quarter.
2. Repayments to Cerner: In the event an Associate's employment is terminated for any reason, voluntarily or involuntarily, and such Associate owes penalties or is required to return commissions,
PAGE 2 EFFECTIVE DATE: JANUARY 1, 2005
Advances or other monies to Cerner, Cerner may deduct the amounts owed from all accounts due to such Associate, such as salary, Advances, vacation, expense reimbursement or commission payments, and the Associate will be liable for the balance, if any. |
Capitalized terms in this plan have the meanings set forth in the CPP Glossary or the contents of this document.
PAGE 3 EFFECTIVE DATE: JANUARY 1, 2005
.
.
.
EXHIBIT 21
SUBSIDIARIES OF REGISTRANT
STATE/COUNTRY OF NAME INCORPORATION 1. BeyondNow Technologies, Inc. Kansas 2. Cerner Belgium, Inc. Delaware 3. Cerner Campus Redevelopment Corporation Missouri 4. Cerner Canada Limited Delaware 5. Cerner Citation, Inc. Delaware 6. Cerner Corporation PTY Limited New South Wales (Australia) 7. Cerner Deutschland GmbH Germany 8. Cerner DHT, Inc. Delaware 9. Cerner Healthcare Solutions Private Limited India 10. Cerner Health Connections, Inc. Delaware 11. Cerner Iberia, S.L. Spain 12. Cerner Innovation, Inc. Delaware 13. Cerner International, Inc. Delaware 14. Cerner Investment Corp. Nevada 15. Cerner Limited United Kingdom 16. Cerner Middle East FZ-LLC Emirate of Dubai, UAE 17. Cerner Multum, Inc. Delaware 18. Cerner Physician Practice, Inc. Delaware 19. Cerner Project IMPACT, Inc. Delaware 20. Cerner Properties, Inc. Delaware 21. Cerner, SAS France 22. Cerner Singapore Limited Delaware 23. Cerner (Malaysia) SDN BHD Malaysia 24. Image Devices GmbH Germany |
EXHIBIT 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders
Cerner Corporation:
We consent to the incorporation by reference in the Registration Statements (No. 333-77029, No. 333-93379, No. 333-63226, No. 333-24899, No. 333-24909, No. 333-75308, No. 333-70170, No. 33-56868, No. 33-55082, No. 33-41580, No. 33-39777, No. 33-39776, No. 33-20155, No. 33-15156, No. 333-40156) on Form S-8, Registration Statement No. 33-72756 on Form S-3, and Registration Statement No. 333-72024 on Form S-4 of Cerner Corporation and our reports dated March 11, 2005, with respect to the consolidated balance sheets of Cerner Corporation as of January 1, 2005 and January 3, 2004, and the related consolidated statements of operations, changes in equity, and cash flows for each of the years in the three-year period ended January 1, 2005, and the related consolidated financial statement schedule, management's assessment of the effectiveness of internal control over financial reporting as of January 1, 2005 and the effectiveness of internal control over financial reporting as of January 1, 2005, which reports appear in the 2004 annual report on Form 10-K of Cerner Corporation.
Kansas City, Missouri
March 16, 2005
EXHIBIT 31.1
CERTIFICATION OF CHIEF FINANCIAL OFFICER
I, Neal L. Patterson, Chief Executive Officer of Cerner Corporation, certify that:
1. I have reviewed this annual report on Form 10-K of Cerner Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: March 17, 2005 /s/Neal L. Patterson Neal L. Patterson Chief Executive Officer |
EXHIBIT 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
I, Marc G. Naughton, Chief Financial Officer of Cerner Corporation, certify that:
1. I have reviewed this annual report on Form 10-K of Cerner Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: March 17, 2005 /s/Marc G. Naughton Marc G. Naughton Chief Financial Officer |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION. 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the filing of the Annual Report on Form 10-K for the fiscal year ended January 1, 2005 (the Report) by Cerner Corporation (the Company), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/Neal L. Patterson Neal L. Patterson, Chairman of the Board and Chief Executive Officer March 17, 2005 |
A signed original of this written statement required by Section 906 has been provided to Cerner Corporation and will be retained by Cerner Corporation and
furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION. 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the filing of the Annual Report on Form 10-K for the fiscal year ended January 1, 2005 (the Report) by Cerner Corporation (the Company), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/Marc G. Naughton --------------------- Marc G. Naughton, Senior Vice President, Treasurer and Chief Financial Officer March 17, 2005 |
A signed original of this written statement required by Section 906 has been provided to Cerner Corporation and will be retained by Cerner Corporation and
furnished to the Securities and Exchange Commission or its staff upon request.